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The global burden of heart disease increases every year. It has been estimated that by the 
year 2020, coronary artery disease (CAD) will be the number one cause of death worldwide. 
Indian populations throughout the world have the highest prevalence of CAD and early onset 
of the disease compared to other ethnic groups.  
Glutathione S-transferases (GSTs) detoxify environmental agents which influence the 
onset and progression of disease. Dysfunctional detoxification enzymes are responsible for 
prolonged exposure to reactive molecules and can contribute to endothelial damage, an 
underlying factor in CAD. Uncoupling proteins (UCPs) 2 and 3 play an important role in the 
regulation of oxidative stress which contributes to chronic inflammation. Coronary artery 
disease is a chronic inflammatory disorder characterized by elevated levels of C-reactive 
protein (CRP) and pro-inflammatory cytokines such as interleukin 6 (IL-6). Polymorphisms of 
these genes have been linked to CAD and other chronic diseases. 
Statins, metabolised in the liver, are the most commonly used drug to control 
atherosclerosis progression in CAD patients. The pleiotropic effects of statins have been 
attributed to both favourable and adverse outcomes in CAD patients particularly related to 
myopathy and hepatotoxicity.   
All patients (n=102) recruited into this study were South African Indian males. A 
corresponding age-, gender- and ethnicity-matched control group (n=100) was also recruited. 
The frequency of the GSTM1 +/0, GSTP1 A105/G105, IL6 -174G/C and CRP -390C/A/T 
genotypes was assessed by polymerase chain reaction (PCR) and PCR restriction fragment 
length polymorphism (PCR-RFLP).  
For the in vitro study, the biological effect of atorvastatin on HepG2 cells was 
assessed. The metabolic activity, cytotoxicity, oxidative stress and nitric oxide production was 
xiv 
 
assessed by the ATP, lactate dehydrogenase (LDH), thiobarbituric acid reactive substance 
(TBARS) and Griess assays, respectively. The profile of 84 microRNA (miRNA) species was 
evaluated using the miRNA Pathway Finder PCR SuperArray. The predicted targets of up-
regulated miRNAs were determined using the online software, Targetscan. The mRNA levels 
of guanidinoacetoacetate (GAMT), arginine glycine aminotransferase (AGAT) and spermine 
oxidase (SMO) were determined using quantitative PCR. Western blotting was used to 
determine GAMT and phosphorylated p53 levels in treated cells.  
The GSTM1 0/0 and GSTP1 A105/A105 genotypes occurred at higher frequencies in 
CAD patients compared with the control group (36% vs. 18% and 65% vs. 48%, respectively). 
A significant association with CAD was observed in GSTM1 0/0 (odds ratio (OR)=2.593; 95% 
confidence interval (CI) 1.353 - 4.971; p=0.0043) and GSTP1 A105/A105 OR=0.6011; 95% CI 
0.3803 - 0.9503; p=0.0377). We found a significant association between smoking and CAD; 
the presence of either of the respective genotypes together with smoking increased the CAD 
risk (GSTP1 A105 relative risk (RR)=1.382; 95% CI 0.958 - 1.994; p=0.0987 and GSTM1 null 
RR=1.725; 95% CI 1.044 - 2.851; p=0.0221). 
The UCP2 -866G/A and UCP3 -55C/C genotypes occurred at highest frequency in 
CAD patients (59% vs. 52% and 66% vs. controls: 63% respectively) and did not influence the 
risk of CAD. Homozygous UCP3 -55T/T genotype was associated with highest fasting 
glucose (11.87±3.7mmol/L vs. C/C:6.11±0.27mmol/L and C/T:6.48±0.57mmol/L, p=0.0025), 
HbA1c (10.05±2.57% vs. C/C:6.44±0.21% and C/T:6.76±0.35%, p=0.0006) and triglycerides 
(6.47±1.7mmol/Lvs. C/C:2.33±0.17mmol/L and C/T:2.06±0.25mmol/L, p<0.0001) in CAD 
patients.  
A significant association between the G allele of the IL6 -174 polymorphism and non-
diabetic CAD patients was found (p=0.0431 odds ratio: 1.307, 95% CI: 1.047-1.632). A 
xv 
 
significant association with the C allele of the -390 CRP triallelic variants and CAD (p=0.021 
odds ratio: 1.75, 95% CI: 1.109-2.778) was also found using a contingency of the C allele vs. 
the minor A and T allele frequencies. The strength of the association of the C allele with non- 
diabetic CAD subjects was much higher (p=0.0048 odds ratio: 2.634, 95% CI: 1.350-5.138).  
Circulating median levels of IL-6 (0.9 (0.90, 0.91) pg/ml and 0.9 (0.87, 0.92) pg/ml) and 
CRP (5.65 (1.9, 8.2) mg/l and 2.90 (1.93, 8.35) mg/l) were similar between CAD patients and 
controls, respectively. A similar finding was observed between controls and non-diabetic CAD 
subjects.  
Levels of IL-6 and CRP in CAD subjects were not significantly influenced by 
polymorphic variants of IL-6 and CRP. In the control group, the level of IL-6 was significantly 
influenced by the IL6 -174 G allele (p=0.0002) and the CRP -390 C allele (p=0.0416), where 
subjects with the homozygous GG (0.9 (0.9, 1,78) pg/ml) and CC (0.9 (0.9, 0.95) pg/ml) 
genotype had higher levels than the C allele carriers (0.9 (0.64, 0.91) pg/ml) or A and T 
carriers (0.9 (0.69, 0.91) pg/ml) combined. 
The lowest measure of proliferation/metabolism in HepG2 cells was observed at 20µM 
atorvastatin, with 82±9.8% viability. The level of cytotoxicity was increased in statin treated 
cells from 0.95±0.02 units to 1.11±0.03 units (p=0.001) and malondialdehyde levels was 
reduced from 0.133±0.003 units to 0.126±0.005 units (p=0.009) whilst nitrite levels were 
elevated (0.0312±0.003 units vs. control: 0.027±0.001 units, p=0.044).  
MicroRNAs most significantly upregulated by atorvastatin included miR-302a-3p (3.05-
fold), miR-302c-3p (3.61-fold), miR-124-3p (3.90-fold) and miR-222-3p (4.4-fold); miR-19a-3p, 
miR-101-3p and let-7g were downregulated (3.63-fold, 2.92-fold, 2.81-fold, respectively). A list 
of miRNA targets identified included those with a role in metabolism and inflammation. The 
miR-124a specifically targets the mRNA of GAMT and SMO.  
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A 1.8-fold decrease in GAMT, a 1.15-fold decrease in SMO, and a 1.53-fold increase 
in mRNA levels was observed following atorvastatin treatment. The protein level of GAMT 
was relatively lower than the untreated control (1.11-fold). The highest level of p53 
phosphorylation was observed in atorvastatin treated HepG2 cells (3.2-fold increase).  
The finding from this investigation indicates that the genetic polymorphisms in 
GSTM1, GSTP1 genes and promoter regions (-174 and -390) of IL-6 and CRP, respectively, 
may influence the risk of young South African Indians to CAD. The in vitro investigation 
provides evidence for the influence of atorvastatin on hepatocytes’ metabolism. A 
mechanism of compromised creatine synthesis by statins has also been described for the 
first time. Taken together, the genetic analysis result shows the complexity of mechanisms 
involved in CAD development. The in vitro aspect further confirms the multifaceted influence 
of therapeutics such as statins in controlling CAD progression and the related adverse 
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Cardiovascular disease (CVD) is amongst the major causes of death worldwide (Mathers and 
Loncar, 2006); (World Health Organisation, 2012). Originally thought to be a disease of the 
developed countries, the prevalence of heart disease is rapidly increasing in developing 
countries, particularly within populations of Indian ethnicity (Brooks et al., 2006). This is true 
for the increase in coronary artery disease (CAD) and type II diabetes mellitus (T2D) 
morbidity in South Africa (SA). The progression of CAD usually occurs gradually from 
childhood into the fifth and sixth decades of life. It is only during the late fifties and sixties that 
the symptoms and clinical indications of fully blown CAD manifest. However, the age of onset 
is now decreasing by at least 15 to 20 years, raising great concern. This is observed most 
especially in the SA Indian population as well as Indian populations in the United States of 
America and the United Kingdom. 
 
Research shows that the onset of CAD is multi-factorial and is influenced by genetic and 
environmental factors as well as lifestyle. Such genetic changes that contribute to disease 
susceptibility include gene insertions or deletions, copy number variants (CNVs) and single 
nucleotide changes (Harris, 1971).  
 
The occurrence and implication of single nucleotide polymorphisms (SNPs) – in CAD and 
T2D – of the detoxification enzyme glutathione-S-transferase (GST) isozymes (GSTP1 and 
GSTM1) (Zanobetti et al., 2011), oxidative stress modulating mitochondrial (mt) uncoupling 
protein 2 (UCP2), uncoupling protein 3 (UCP3) (Hamada et al., 2008) and inflammatory 
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cytokines interleukin-6 (IL-6) (Tilg and Moschen, 2006) and C-reactive protein (CRP) (Miller et 
al., 2005) has been well documented. 
 
Oxidative stress, the underlying mechanism for pathology in T2D is a predisposing condition 
for the development of atherosclerosis and CAD. Hyperglycaemia induces increased 
superoxide production in mitochondria of endothelial cells that leads to the pathogenesis of 
T2D complications (Brownlee, 2001). The presence of SNPs in genes such as GST may 
positively or negatively impact an individual’s ability to detoxify reactive oxygen species 
(ROS) and their products. Consequently, variation in individual specific susceptibility to 
pathologies associated with disease is frequently observed (Priscilla and Prince, 2009).  
 
Mitochondrial (mt) uncoupling proteins are transmembrane proteins that discharge the proton 
gradient generated during oxidative phosphorylation. The roles of UCP2 and UCP3 are 
unclear, though, they have been associated with the protection against oxidative damage, 
ageing and degenerative diseases (Affourtit et al., 2007). A number of studies have linked 
UCPs with disease prevalence, particularly diabetes (Hagen and Vidal-Puig, 2002) and 
obesity (Surwit et al., 1998). These conditions are often associated with patients that suffer 
from CAD. Interestingly, mt UCPs have also been implicated in heart failure (Laskowski and 
Russell, 2008). Uncoupling proteins are considered key regulators of energy and glucose 
metabolism (Lee et al., 2008). As a result, the optimum functioning of UCPs is essential. 
Studies that investigated the UCP gene polymorphisms UCP2 -866 G/A (Laskowski and 
Russell, 2008) and UCP3 -55 C/T (Cassell et al., 1999) have implicated a structural and 




Interleukin-6, a multi-functional cytokine responsible for acute inflammatory responses, and 
CRP, an acute phase protein produced by hepatocytes, are implicated in the pathogenesis of 
CAD. Chronic inflammation in CAD is mediated by IL-6. C-reactive protein expression is 
primarily induced by IL-6 and synergistically enhanced by IL-1β and to a lesser extent tumour 
necrosis factor alpha (TNFα) (Rhodes et al., 2011). In CAD, the chronic stimulation of CRP 
prolongs immune activation and inflammation. Single nucleotide polymorphisms in the 
promoter regions of the genes for inflammatory cytokines influences cytokine levels and is 
strongly implicated in the development and progression of inflammatory conditions (Olivieri et 
al., 2002; Hage and Szalai, 2007; Shanker and Kakkar, 2010; Yeh et al., 2010; Najar et al., 
2011; Pereira et al., 2011).  
 
Oxidative stress and inflammation have been investigated individually with respect to the 
development of CAD and progression to heart failure. The communication between these 
processes, however, begins from initiation to development and progression of atherosclerotic 
lesions in CAD. The vicious cycle between oxidative stress and inflammation manifests in 
shared elements (in circulation, intracellularly and in the plaque core) resulting in a chronic 
inflammatory response observed in CAD. 
 
An important mechanism of epigenetic control of immunological processes is via miRNA 
expression. MicroRNAs are small, non-coding RNA species that regulate protein expression 
through post-transcriptional repression or degradation of messenger RNA (mRNA) species 
prior to translation (Asirvatham et al., 2008; Kai and Pasquinelli, 2010). The role of miRNAs in 
plaque development, vascular function (Small et al., 2010), inflammation (Hoekstra et al., 
2010) and heart failure (Tijsen et al., 2010, Elton et al., 2011) has recently been investigated. 
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Epigenetic modifications, especially changes in miRNA expression are affected by 
therapeutics such as statin therapy. These modifications influence disease progression and 
improve the prognosis of CAD patients.  
 
The statin family of drugs is widely used for reducing cholesterol levels and decreasing the 
incidence of CAD (Zhao et al., 2009).  The target of statin therapy is the 3-hydroxymethyl-3-
glutaryl Coenzyme A reductase (HMGCR) - a key rate-limiting regulatory enzyme in 
cholesterol synthesis (Baetta and Corsini, 2009) which occurs in the liver. An increase in 
cholesterol levels in the liver have been shown to induce a change in gene expression and 
activity of hepatocytes. These changes include switching to a predominant inflammatory state 
by increasing pro-inflammatory cytokine (IL-1, TNFα and IFNγ) signalling pathways 
(Kleemann et al., 2007).  A range of pleiotropic effects from this family of drugs have been 
observed. These range from reducing oxidative stress and inflammation (Grothusen et al., 
2005) to adverse effects of fatigue and myopathy (Phillips et al., 2002).  
 
To date, there are no reports on the relationship of GSTP1, GSTM1, UCP2, UCP3, IL-6 and 
CRP polymorphisms in the SA Indian population presenting with CAD. In addition, no 
epigenetic study (miRNA) has been conducted in this population group. This necessitates 
studies to be conducted in SA to determine if these polymorphisms or epigenetic changes are 
linked to the high incidence of CAD. Establishing a link could offer the possibility of genetic 
screening of patients to determine patient predisposition to CAD and for the early 








STUDY RATIONALE AND AIMS 
 
Genetic investigations provide clues on the understanding of the underlying mechanisms of 
atherosclerosis and CAD. Many of these genetic studies are conducted in the developed 
world and as such it is difficult to extrapolate this data to diseases in the developing world. 
Most SA Indians are descendants of indentured labourers who were brought to KwaZulu-
Natal from India between 1860 and 1911. In 2006, reports still showed that the highest death 
rates for CAD in SA occur in Indians (Norman et al., 2006). This suggests that regardless of 
the 150 years that Indian immigrants have lived in SA, there remains a differing pattern of 
CAD mortality compared to the natives of the country, despite them sharing the same 
environment and to some extent similar diets and cultural habits (Lal, 2004). 
 
It has now become necessary to assess these influences in our local Indian population, 
especially those predisposed to CAD.   
 
The role of the liver as a central metabolic organ was then evaluated. The potential of statins 
to influence liver function enzymes and play a role in non-alcoholic fatty liver disease has 
been described. The liver is a rich source of molecules required by peripheral tissue, which 
include a range of nutrients, lipid transport proteins, and acute phase proteins, to name a few. 
The effect of atorvastatin, a commonly prescribed drug in CAD patients, was investigated on 
a human liver cell line (HepG2). We investigated the epigenetic effect of upregulated miRNAs 
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on selected targets obtained from a list of predicted targets using the TargetScan online 
software. It was then speculated that from an analysis of miRNAs and their targets, a possible 
novel mechanism of action of statins may be determined.  
 
The aim of this study was to evaluate why SA Indians are more susceptible to early onset of 
CAD by assessing selected genetic (SNPs). In addition, the biological and epigenetic effect of 
atorvastatin on a human liver cell line was evaluated. 
  
The objectives of this study were designed to assess:-  
 
A: Young SA Indian CAD patients for single nucleotide genetic changes in:-  
i) Detoxification enzymes - GSTP1 (codon 105) and GSTM1 (gene deletion) 
ii) Oxidative stress modulators - UCP2 -866G/A and UCP3 -55C/T promoter SNPs 
iii) Pro-inflammatory markers – IL-6 -174G/C and CRP -390 C/A/T promoter SNPs 
 
B: To assess the effect of atorvastatin in the HepG2 liver cells:- 
i) Measure the metabolic activity/cell proliferation  
ii) Determine the epigenetic changes in miRNAs in HepG2 cells and their potential 











1.1 Overview of Coronary Artery Disease 
 
Atherosclerosis and thrombosis are the two major contributing mechanisms in CAD, a major 
health problem and one of the leading causes of global death (World Health Organisation, 
2012).  
 
Atherosclerosis is a chronic inflammatory vessel disorder characterised by lipid deposition 
and formation of fibrous plaques on the arterial wall, which over a lengthy period of time 
becomes unstable as a result of multiple factors leading to clinical symptoms of heart disease 
(Figure 1.1) (Libby, 2002; Ross, 2005; Watkins and Farrall, 2006). The process of 
atherogenesis activates the immune response that involves a host of inflammatory cells and 
cytokines (Libby, 2002). The development of atherosclerotic lesions is amplified by chronically 
high levels of ROS (McGill et al., 2000; Watkins and Farrall, 2006). 
 
In the past centuries, CAD has undeniably been under-estimated with respect to the huge 
impact it has on the global economy. The exponential increase in the global burden of CAD 
and T2D are two examples of non-communicable diseases (NCDs) that have been neglected. 
Both diseases occur as a result of multiple factors ranging from genes to environmental 





Figure 1.1 Schematic development and progression of an atherosclerotic plaque and 
clinical manifestation of acute myocardial infarction (Libby, 2002). 
 
 
1.2 Epidemiology of CAD 
 
The World Health Statistics of 2012 estimates that “57 million global deaths in 2008, 36 
million (63%) were due to NCDs. Population growth and increased longevity are leading to a 
rapid increase in the total number of middle-aged and older adults, with a corresponding 
increase in the number of deaths caused by NCDs. It is projected that the annual number of 






Figure 1.2: Global view for the probability of death (%) from non-communicable 
diseases between the ages of 30 and 70 as at 2008 (World Health Organisation, 2012). 
 
Non-communicable disease risk factors are known; the largest proportion of NCD deaths is 
caused by CVD (48%), followed by cancers (21%) and chronic respiratory diseases (12%). 
Diabetes is directly responsible for 3.5% of NCD deaths (Figure 1.2) (World Health 
Organisation, 2012).  
 
1.3 Classification of CAD risk factors 
 
Risk factors associated with cardiac failure are classified as modifiable and non-modifiable 
risk factors. Modifiable risk factors are risk factors that occurs as a result of circumstance and 
are under the control of an individual, and this includes behavioural risk factors. Non-








Symptomatic CAD is usually prevalent in individuals over the age of 60 and was considered a 
disease of the aged/elderly. This, however, is changing as individuals are presenting with 
coronary artery syndromes as early as mid-twenties, a statistic that is notable amongst Indian 
patients in SA. In a study on CAD in Indians, approximately half of all myocardial infarctions 
occurred in individuals under the age of 50, with 25% being under 40 years of age (Enas et 
al., 2001). A recent study found no relationship between obesity-related polymorphisms and 
the metabolic syndrome in 485 young (≤ 45 years) SA Indian patients with acute myocardial 






Type II Diabetes mellitus is classified as a disease that can either be inherited or acquired, 
in which the likelihood of acquisition is much higher if both parents have the disease. The 
mechanisms by which diabetic complications influence atherosclerotic development range 
from microvascular complications of retinopathy and nephropathy to neuropathy. This is a 
result of hyperglycaemia induced oxidative stress, pro-inflammatory cytokine production 





Figure 1.3: Hyperglycaemia-induced activation of protein kinase C (PKC) which 
influences cardiovascular function, increases diacylglycerol (DAG), and nitric oxide 
production. Activated PKC also affects endothelin-1 (ET-1), vascular endothelial 
growth factor (VEGF), transforming growth factor-b (TGF-b) and plasminogen activator 
inhibitor-1 (PAI-1), NF-kB and NAD(P)H oxidases (Brownlee, 2001). 
 
In addition, the chronic hyperglycaemia associated with diabetes modifies protein structure 
and function due to glycosylation of amino acid residues. Glycated proteins and growth 
factors such as insulin stimulate the proliferation of smooth muscle cells. Type 2 diabetes 
mellitus is also associated with elevations of PAI-1 and alterations in the lipid profile such as 
elevated triglycerides and low density lipoprotein cholesterol (LDL-C) and reductions in high 
density lipoprotein cholesterol (HDL-C) (Brownlee, 2001; Wagner et al., 2002). Taken 
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Adult women are less likely to develop heart disease compared to males due to the cardio-
protective effects of oestrogen. Other factors such as oral contraceptives and smoking, 
however, alter this protection and the risk of developing coronary syndromes increases (Tanis 
et al., 2001).  
 
A recent study published in the New England Journal of Medicine evaluated the role of the Y 
chromosome in CAD (Charchar et al., 2012). Three study cohorts of 3233 men of British 
origin were included in the study and their Y chromosomes were tracked back to 9 different 
lineages, which they defined as haplogroups.  
 
It was shown that British men who inherited haplogroup I had an approximately 50% higher 
risk of CAD than men with other types of the Y chromosome, irrespective of age, body-mass 
index, blood pressure, lipids, diabetes, smoking, alcohol consumption, socioeconomic status, 
or circulating concentrations of CRP. A further transcriptomic analysis of men with haplogroup 
I presented with a reduced adaptive immunity and increased inflammatory response 
pathways in their macrophages compared with carriers of other Y chromosome types. This 
indicates that predisposition to CAD is “most likely mediated through immune response” 






The high incidence of CAD in SA Indians in Durban was first reported in 1969 (Wainwright, 
1969). More than 40 years later, epidemiological data in SA shows that Indians have the 
highest mortality (the rate of deaths in a population) for CAD, followed by mixed ethnicity, 
white and black (Norman et al., 2006).  
 
A global case-control study of the risk factors of acute myocardial infarction called the 
INTERHEART study investigated the association of risk factors for acute myocardial 
infarctions in relatively young native South Asians (mean age of 53 years), compared with 
individuals from other countries (mean age of 58 years). They found that apolipoproteins: 
(apo) apoB/apoA-1 ratios were found to have the highest attributable risk among South 
Asians (n=10 728) compared to individuals from other countries (n=12 431) (Joshi et al., 
2007).  
 
The Framingham Heart Study: Impact on the Prevention and Control of Cardiovascular 
Diseases in India reported in 2010, reported their assessment of the changing disease profile 
in India. The results from this study indicate that the classical risk factors that determine the 
CVD play a role in all populations and ethnic groups (Reddy and Satija, 2010).  
 
It was recommended, however, that Indians be classified as a high risk group, and the 
classical ranges for risk factors be evaluated when calculating the Framingham score (a risk 





1.3.2 Modifiable risk factors  
 
1.3.2.1 Behavioural risk factors 
 
Behavioural risk factors contribute to 80% of coronary heart disease and cerebrovascular 
disease. These include tobacco use, physical inactivity, unhealthy diet and the consumption 
of alcohol. These risk factors are associated with four key changes in metabolism and 
physiology i.e. elevated blood pressure, overweight leading to obesity, hyperglycaemia and 
hyperlipidaemia.  
 
These changes can have multiple effects. “For example, in addition to its direct role in 
diabetes, raised fasting blood glucose also increases the risk of cardiovascular deaths, and 
was estimated to cause 22% of coronary heart disease-related deaths and 16% of stroke-
related deaths. In terms of attributable deaths, the leading behavioural and physiological risk 
factors globally are raised blood pressure (to which 13% of global deaths are attributed), 
followed by tobacco use (9%), raised blood glucose (6%), physical inactivity (6%) and being 
overweight or obese (5%)” (World Health Organisation, 2012).  
 
1.3.2.1.1 Tobacco Use 
 
Cigarette smoking is associated with adverse changes in several components of 
cardiovascular physiology, including endothelial cell dysfunction, and leukocyte and platelet 
activation. Cigarette smoking is associated with first and recurrent coronary events, a lower 
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HDL-C, endothelial cell dysfunction, platelet aggregation, plaque rupture, oxidative stress and 
mt DNA damage.  
 
Smoking may increase acute coronary events and strokes by increasing inflammation and 
thrombosis (Bazzano et al., 2003).  Free oxygen radicals derived from cigarette smoke lead to 
increased oxidative stress and decreased nitric oxide production (Blann et al., 1998). 
Antioxidant capacity is compromised as a result of smoke-derived free radical scavenging, 
losing the capacity to protect against endogenous free radicals produced through normal 
respiration. This process contributes further to levels of oxidized-low density lipoprotein – 
cholesterol (oxLDL-C) and atherosclerotic lesion progression. In addition, nicotine is a strong 
activator of the sympathetic nervous system, which releases catecholamines that interfere 




Hypertension is a very common disease experienced by approximately 30% of all adults. 
Commonly referred to as the ‘silent killer’, hypertension is largely asymptomatic and puts 
strain on the heart and arterial system resulting in mechanical damage to the endothelium 
lining, promoting the onset of atherosclerosis. 
 
Approximately 51% of stroke-related deaths and 45% of coronary heart disease-related 
deaths occur as a consequence of elevated blood pressure. Reports from the World Health 
statistics from 2012 showed that the mean blood pressure decreased dramatically in nearly all 




In the United States of America, the mean age-standardized male systolic blood pressure 
(SBP) decreased from 131 mm Hg (95% uncertainty interval 127–135) in 1980 to 123 mm Hg 
(120–127) in 2008, while mean age-standardized female SBP decreased from 125 mm Hg 
(121–130) to 118 mm Hg (115–122) mm Hg. In contrast, mean blood pressure has been 
increasing in most African countries (World Health Organisation, 2012).  
 
The major cause of elevated blood pressure is due to dietary intake of salt but more 
importantly, psychological stress. Both diet and stress factors have been addressed in the 
developed world countries. Experts believe that developing countries can reduce the mortality 




1.3.2.3 Diet and Physical Inactivity 
 
A high-fat and carbohydrate diet with high glycaemic index impairs endothelial function 
directly and indirectly. A cholesterol-rich diet directly increases in LDL-C concentrations. A 
high carbohydrate diet can lead to hyperglycaemia which indirectly influences oxidative 
stress, inflammation and PKC activation (as described under hereditary factors: ‘Diabetes’). 
Epidemiologic studies show an inverse relationship between dietary intake of antioxidant 




According to the World Health statistics, 2.8 million people die yearly as a result of being 
overweight or obese. “Being overweight or obese can lead to adverse metabolic effects on 
blood pressure, cholesterol and triglyceride levels, and can result in T2D. Being overweight or 
obese thus increases the risks of CAD, ischaemic stroke and T2D. Between 1980 and 2008, 
the worldwide prevalence of obesity (body mass index (BMI) ≥30 kg/m2) almost doubled. By 
2008, 10% of men and 14% of women in the world were obese, compared with 5% of men 
and 8% of women in 1980. As a result, an estimated half a billion men and women over the 
age of 20 were estimated to be obese in 2008. In all World Health Organisation regions, 
women were more likely to be obese than men” (World Health Organisation, 2012).  
 
In contrast, regular exercise has been shown to consistently improve endothelial function, 
improve insulin sensitivity and reduce the risk for development of coronary heart disease.  
 
 
1.4 The pathophysiology of coronary artery disease 
 
The architecture of the normal human coronary artery comprises a tri-laminar structure (Libby, 
2002). The layer in direct contact with circulating molecules is the endothelial cell layer which 
rests on a basement membrane. The endothelium is regarded as an endocrine organ as it 
releases one or more factors involved in local vasodilation (Vogel, 1997). The intimal layer 
lies below the endothelium and consists of smooth muscle cells in an intimal extracellular 
matrix. The internal elastic lamina creates a barrier between the tunica intima and media. The 
media is made up of tightly packed multiple layers of smooth muscle cells embedded in a 




Endothelial cell injury is initiated by increased shear stress caused by the combination of high 
blood viscosity, hypertension and vasoconstriction - providing the opportunity for the 
formation of atherosclerotic lesions or fatty streaks.  
 
During the early stages of the development of an atherosclerotic plaque, endothelial cell injury 
occurs. This leads to endothelial cell dysfunction and expression of adhesion molecules which 
recruits inflammatory cells via leukocyte adhesion and infiltration. A damaged endothelial 
layer also promotes the entry and accumulation of lipids, of which apo B in LDL-C in particular 
undergoes oxidative modification to form extensively oxLDL-C (Navab et al., 1996; Witztum 
and Palinski, 1999). 
  
 
Figure 1.4 Molecular and cellular processes from initiation to rupture of an atheroma 
(Watkins and Farrall, 2006). 
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The monocytes, which have migrated into the subendothelial space, differentiate into 
macrophages and take up oxLDL-C by phagocytosis. This leads to foam cell formation. 
Oxidized LDL-C taken up by scavenger receptors undergo esterification and are stored in lipid 
droplets. The more soluble forms are exported to extracellular HDL-C acceptors via 
cholesterol transporters (Glass and Witztum, 2001).  
 
Macrophages take on a characteristic foamy appearance, and become activated which leads 
to a state of chronic inflammation. This results in a lipid-rich core in the intima (Glass and 
Witztum, 2001; Libby, 2002) that causes the artery to enlarge in an outward direction (Libby, 
2002; Ross, 2005; Watkins and Farrall, 2006).  
 
The lipid-rich core and dysfunctional endothelium induces the recruitment of inflammatory 
cells. This further contributes to an inflammatory state. Inflammation and persistent 
dyslipidaemia are factors that promote the growth of the lipid core. As a result, activated 
leukocytes release proteinases which degrade the extracellular matrix components. These 
changes render the plaque fragile and susceptible to rupture (Figure 1.4) (Watkins and 
Farrall, 2006).  
 
A ruptured plaque interacts with tissue factor in circulation and induces the coagulation 
cascade and thrombus formation. If the thrombus occludes the vessel persistently, it results in 






1.4.1 The role of lipids in plaque development 
 
The source of serum cholesterol stems from endogenous production in the liver or from the 
diet. Serum cholesterol is transported by low density and high density lipoprotein molecules. 
Although LDL-C has an essential function of cholesterol delivery to peripheral tissue, 
excessive amounts of LDL-C in circulation increases the risk of CAD (Libby, 2002). LDL-C is 
recognized by LDL-C receptors of cells due to the N-terminal domain of the apo-B100 
component. LDL-C receptor expression is controlled by the transcription factor sterol 
regulatory-element binding proteins (SREBPs), which are activated when low intracellular 
levels of cholesterol are detected.  
 
Statins, the most prescribed drug in the world, are used in the management of CAD patients 
to reduce total cholesterol and LDL-C levels and improve HDL-C levels (Dirks and Jones, 
2006). Statins inhibit endogenously synthesized LDL-C by competitive inhibition of HMGCR 
(the rate-limiting enzyme of cholesterol synthesis), enhancing the clearance of LDL-C from 
circulation and reducing the availability of LDL-C to contribute to atherosclerosis.  
 
Statins have been shown to possess anti-inflammatory properties by reducing the activation 
of TNF-α-induced hypoxia-inducible factor-1α and inhibiting platelet aggregation 
(Chandrasekar et al., 2006). The antioxidant effects of statins were demonstrated in a 
monocyte cell line via the inhibition of superoxide radical production by nicotinamide adenine 




In a clinical setting, the dose of statin prescribed is dependent on the statin type. The dose 
range falls between 20mg to 80mg per day, with a plasma half-life of between 2-4 hours, with 
the exception of atorvastatin which has a longer half-life (14-20 hours) (Chong et al., 2001; 
Manzoni and Rollini, 2002).  The statin family of drugs are generally well tolerated in patients, 
but approximately 11% of cases present with skeletal muscle myopathy that include muscle 
pain, stiffness, cramp and fatigue, and rare cases of severe rhabdomyolysis (Chong et al., 
2001; Bruckert, 2005).  
 
 
1.4.2 Inflammation and atherosclerosis 
 
At the site of the atherosclerotic lesion the initiating cytokine, macrophage-colony stimulating 
factor (M-CSF) promotes monocyte differentiation into macrophages (Figure 1.5). An 
investigation on mutated mice lacking M-CSF showed a drastic reduction in macrophage 
accumulation and lesion development (Smith et al., 1995).  
 
The differentiation of monocytes to macrophages also induces expression of toll like receptors 
(TLRs) and pattern-recognition receptors for innate immune activation (Janeway and 
Medzhitov, 2002; Peiser et al., 2002). Cell particles from apoptosis as well as oxLDL-C are 
internalized by macrophages as they contain pathogen-like molecular patterns, which are 
recognized by scavenger receptors (Peiser et al., 2002). It is this source of oxLDL-C that 




Toll-like receptors are also expressed on mast cells and endothelial cells. The binding of the 
oxLDL recognised as ‘foreign’ molecules to TLRs can initiate a signal cascade that induces 
cell activation (Janeway and Medzhitov, 2002). Once activated macrophages produce a 
range of molecules that promote atherosclerosis. Reactive oxygen species oxidise LDL 
molecules in the lesion, whilst proteases (matrix metallopeptidases) cleave matrix proteins 




Figure 1.5 The (A) activation of inflammatory T-cells and (B) cytokine cascade in 




Activated macrophages also release chemokines (monocyte chemoattractant protein-1 (MCP-
1), IL-8, interferon-gamma (IFNγ), and eotaxin) which promote adhesion molecule expression 
(vascular cell adhesion molecule-1 (VCAM-1), P- and E-selectin).  In vivo studies on mice 
lacking MCP-1 or its receptor CCR2 have lower levels of mononuclear cells at atherosclerotic 
lesions (Boring et al., 1998; Gu et al., 1998). The expression of VCAM-1 is initiated by pro-
atherogenic factors and the initial accumulation of LDL-C in the intima. The expression of 
VCAM-1 is further potentiated by pro-inflammatory cytokines IL-1 and TNFα (Libby, 2002).   
 
The release of these chemokines attracts immune and inflammatory cells (monocytes, 
leukocytes, B and T lymphocytes, and mast cells) to the atherosclerotic lesion. The T cells 
together with macrophages then further contribute to the cytokine milieu by producing IL-1, IL-
6, IFNγ, TNFα, and angiotensin II (Glass and Witztum, 2001; Hansson, 2001) (Figure 1.5).  
 
Atherosclerotic lesions always contain an infiltrate of cells, predominantly cell death (CD) 4 
positive (CD4+) T cells and to a lesser extent CD8+ B cells. Once activated T-cells 
differentiate into T-helper 1 (Th1) and 2 (Th2) cells, they contribute to the cytokine milieu in 
the plaque, particularly IFNγ. Interferon gamma induces synthesis of the pro-inflammatory 
cytokines, IL-1β and IL-6, which are released into circulation. Both IL-1β and IL-6 then 
stimulate the synthesis of acute phase proteins in the liver. This results in a chronic 
inflammatory response that promotes atherosclerosis (Figure 1.5) (Hansson, 2001).  
 
Single nucleotide polymorphisms and mutations in genes of detoxification enzymes, 
modulators of oxidative stress as well as inflammatory cytokines have been shown to 
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influence mRNA levels and protein expression. These genetic changes have thus been 
associated with complex diseases and have become an area of interest for 
pharmacogenomic research.  
 
1.5 The significance of genetic variation in CAD 
 
The decrease in the age for onset of the ‘chronically inflammatory disease’ has been 
attributed to hereditary factors associated with diabetes and obesity and familial-linked CAD. 
This has prompted researchers to assess a possible genetically-related (SNPs, CNVs, 
insertions/deletions) or epigenetic (DNA methylation, chromatin and histone modification and 
miRNA expression) link.  
 
Epigenetic modification by DNA methylation is well understood. This process entails a 
covalent modification of cytosine maintained at CpG islands by methylation catalysed by DNA 
methyl transferases. This methylation then induces gene silencing and chromatin modification 
(Bjornsson et al., 2004). These are stable, heritable changes that do not affect the DNA 
sequence (Li et al., 2009). Abnormal regulation of epigenetic processes, have been linked to 
the onset and progression of several diseases, including CAD (Hmadcha et al., 1999; 








1.5.1 Single nucleotide polymorphisms and gene deletions 
 
Multiple genetic and environmental factors influence an individuals’ susceptibility to disease. 
Unlike inherited monogenic disorders where the presence or absence of a specific allele 
dictates the presence or absence of disease; in complex diseases, the presence or absence 
of risk alleles, in more than 1% of the population, may only mildly increase the probability of 
disease onset (Lander and Schork, 1994; Chakravarti, 1999; Risch, 2000).  
 
In 1971, Harris hypothesized that common DNA variants provide the basis for variation of a 
single enzyme and “are quite possibly the underlying biochemical cause of much of the 
inherited diversity in the physical and physiological characteristics of individuals, and also in 
relative susceptibilities to various diseases and other disorders” (Harris, 1971). The first 
genetic variants tested were usually restriction fragment length polymorphisms (RFLPs), but 
with advancing technology such as the development of the polymerase chain reaction (PCR), 
microsatellites, variable number tandem repeats (VNTRs), insertion/ deletion polymorphisms, 
and SNPs can all be analysed.  
 
Association studies, usually have a case-control design, and compares genotypic variants in 
patients to healthy controls. These types of studies are used to assess the presence of a 
gene variant and relate the frequency at which they occur between groups to susceptibility of 
various diseases. The conclusion of such studies is that the polymorphism being tested either 
affects risk of disease directly or is a marker for nearby genetic variants that affects disease 




The Myocardial Infarction Genetics Consortium (MIGC) has classified early onset myocardial 
infarction as ‘a promising phenotype for genetic mapping’ (Kathiresan et al., 2009). The MICG 
assessed SNPs at nine loci which reached genome-wide significance, three of which were 
newly identified and six that were replicated; and five hundred and fifty four copy number 
variations (CNVs), none of which were significant (Kathiresan et al., 2009).  The observations 
in these studies show associations of SNPs with myocardial infarction lending credence to 
investigations of genetic changes linked to disease risk.   
 
1.5.2 The role of microRNAs in coronary artery disease  
MicroRNAs are a group of small non-coding RNA molecules which were discovered almost 
twenty years ago, but only over the past 5 years has there been an exponential increase of 
research in this field (Bushati and Cohen, 2007; Bartel, 2009). The miRNA registry has 
therefore created a set of standard nomenclature for this set of molecules (Table 1.1, 
(Griffiths-Jones, 2004).  
 
Table 1.1 Nomenclature of miRNAs (Griffiths-Jones, 2004) 
miRNA Nomenclature Example
miRNA
The prefix "mir" is followed by a dash and a number, which is 
attributed sequentially
mir-123 was likely discovered 
before mir-423
Pre-miRNA Indicated by the uncapitalised prefix "mir" mir-155









miRNA that originates from different species The species of origin is designated by a three letter prefix
hsa-miR-155 (Homo sapiens) 
mmu-miR-155 (Mus musculus )
When the relative expression levels of the two mature 
miRNAs originating from opposite arms of the same pre-
miRNA are not known
The suffix -5p is added to the miR originating form the 5' arm 
and -3p is added to the miR from the 3' arm
Two mature miRNAs that have originated from opposite 
arms of the same pre-miRNA, when relative expression 
levels are known
The predominant miR is named as described above and the 
other miR expressed at lower levels is followed by an asterisk
Pre-miRNAs that are located at distinct genomic loci but 
that leaad to identical mature miRNA
Denoted with an additional dash-number suffix
miRNAs with nearly identical sequences (i.e., one or two 
nucleotides different)





Figure 1.6 Concepts of miRNA functions. The potential sites of regulation of gene 
expression by miRNAs are represented in (a) intronic miRNAs encoded within the 
same protein code transcript that regulates similar processes of that protein; (b) a 
single miRNA targets several mRNA targets involved in the same biological process, 
TF, transcription factor; (c) several miRNAs regulate the same biological process by 
targeting individual components of a pathway; (d) miRNAs targets molecules that are 




The newly found interest in miRNAs and their function (Figure 1.6) has been attributed to the 
critical role of these molecules in controlling several biological processes ranging from cell 
differentiation and proliferation to development and apoptosis. MicroRNAs regulate gene 
expression by acting as RNA silencers.  
 
Most miRNA genes are generated from independent transcription units located in regions of 
the genome distant from protein-coding genes but at least 25% of human miRNAs are found 
in the introns of protein-coding genes. The primary transcripts (pri-miRNAs) are normally a 
few kilobases long and are characterized by the presence of stem loop structures (Figure 
1.7).  
 
The maturation of pri-miRNAs occurs via a cascade of reactions. The first reaction is 
catalysed by an enzymatic complex: RNAse III-type protein Drosha and the DiGeorge critical 
region 8 (DGCR8) proteins (Winter et al., 2009). Drosha and DGCR8 catalyse the cleavage of 
pri-miRNAs at the stem of the hairpin resulting in pre-miRNAs. Pre-microRNAs are 
approximately 80 nucleotide bases in length. Not all miRNAs require this type of processing 
as some miRNAs are generated from mirtrons (short intron sequences) with the potential to 
form hairpin loops.  
 
A nuclear transport protein, exportin-5 which functions with GTPase Ran, then transports pre-
miRNAs into the cytoplasm where further processing occurs (Winter et al., 2009). 
Cytoplasmic RNase Dicer, theRNA-binding protein: trans-activation response (TAR) RNA-
binding protein (TRBP) and Argonaute-2 (Ago2) forms part of a multiprotein complex which 
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cleaves off the loop of pre-miRNAs generating 22-nucleotide miRNA duplexes with two 
nucleotides protruding at the 3 prime ends. 
 
 
Figure 1.7 The process of miRNA maturation and regulation (Kai and Pasquinelli, 2010). 
 
Once cleaved and after dissociation from the Dicer and TRBP, the miRNA is unwound and 
the functional strand remains bound to Ago2. The functional strand is complementary to the 
mRNA target associated with Ago2 guides the silencing activity of the RNA-induced silencing 
complex (RISC) effecter complex while the other strand is usually degraded (Figure 1.7, 
(Stefani and Slack, 2006; Mattes et al., 2007; Farazi et al., 2008; Winter et al., 2009; Kai and 




Similar to other cellular processes, aberrant regulation of the expression of miRNAs is linked 
to the onset and progression of several diseases. By regulating gene expression post-
transcriptionally by inhibiting translation and/or induction of protein degradation of specific 
RNAs (Lee et al., 2004), miRNAs have been implicated in contributing to CVDs such as acute 
myocardial infarction (Meder et al., 2011), heart failure (Tijsen et al., 2010), CAD 
(Fichtlscherer et al., 2010; Hoekstra et al., 2010) and stroke (Laterza et al., 2009; Saenger 
and Christenson, 2010).  
 
Research into the modulation of miRNAs has therefore become an appealing idea for the 
treatment of heart disease (van Rooij et al., 2008). Several miRNA mimics and antagonists of 
miRNAs have already advanced to clinical trials (Turchinovich et al., 2011). The role of 
miRNAs in the regulation of inflammatory gene expression in immune cells has been well-
investigated. The liver, however, also plays an integral role in the development of 
atherosclerosis being the source of cholesterol and lipoprotein synthesis, lipid metabolism and 
hepatic inflammation (Kleemann et al., 2007). Therapeutics (such as statins) is able to 
influence these processes and have also been implicated in affecting miRNA expression 
(Takwi et al., 2012; Wang et al., 2012). The significance of miRNAs undoubtedly requires 












GLUTATHIONE-S-TRANSFERASE POLYMORPHISMS AND EARLY-ONSET CORONARY 




Atherosclerosis and thrombosis are the two major contributing mechanisms in CAD. The 
formation of atherosclerotic lesions is augmented by elevated levels of ROS (McGill et al., 
2000). Endothelial cell injury is initiated by increased shear stress caused by the combination 
of high blood viscosity, hypertension and vasoconstriction that may be induced by smoking 
(Nagy et al., 1997; Blann et al., 1998).  
 
Cigarette smoke contains a complex mixture of approximately four thousand different 
chemical species. In addition, cigarette smoke contains plentiful oxygen centred, nitrogen 
centred and carbon centred free radicals which increase ROS generation and promote 
oxidative damage (Koul et al., 2001).  
 
Reactive oxygen species are produced by cells through normal metabolic processes and 
disruption of the mt electron transport chain (Hulsmans and Holvoet, 2009). Cell-intrinsic 
mechanisms, such as the glutathione (GSH) antioxidant defence system act to combat ROS. 
Disturbances in the endogenous antioxidant defence mechanism or ROS overproduction 
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however, leads to accumulation of free radicals which induce oxidative damage to 
biomolecules by lipid peroxidation, protein nitration and DNA adduct formation.  
 
Cellular detoxification systems protect against both endogenous and exogenous harmful 
substances. Of particular interest is the super family of glutathione S-transferase (GST) 
enzymes, which modulate prostaglandin signalling pathways and oxidative stress (Hayes and 
McLellan, 1999).  
 
Human GSTs exist in at least eight different classes (Alpha, Mu, Pi, Theta, Kappa, Zeta, 
Omega, and Sigma), which are assigned based on the similarity of their sequences. The 
metabolic role of GSTs is integral as they function to detoxify electrophilic substrates by 
catalysing their reactions with GSH (Figure 2.1), thereby reducing the interactions between 
reactive electrophiles and DNA, protein and lipids that impairs cellular function (Townsend 
and Tew, 2003).  
 
Glutathione-S-transferases function to detoxify toxicants, including those found in cigarette 
smoke, by facilitating their conjugation to GSH (Sies, 1999). However, GST function is 
influenced by genotypic differences arising from SNPs (Hu et al., 1997).  
 
The GST genes contain several polymorphic variants that occur at high frequency. In the 
GSTP1 variant, there is a single nucleotide change from A to G at codon 105, resulting in an 
isoleucine (Ile) to valine (Val) amino acid change. The GSTM1 variant is the complete deletion 




Figure 2.1 The detoxification reaction catalysed by glutathione-S-transferase 
(Townsend and Tew, 2003). 
 
The genetic susceptibility in response to air pollution and cardiovascular outcomes showed 
that GSTP1 and GSTM1 played a role in ROS modulation (Zanobetti et al., 2011). Other 
studies also found an association of the GSTM1 null genotype with heart failure (Chahine et 
al., 2007; Madrigano et al., 2010).  
 
A study by Madrigano et al. (2010) found that black carbon and particulate matter exposure 
was associated with increased intracellular and vascular cell adhesion molecules. These 
molecules promote atherosclerosis. The association they found was modified by the presence 
of the GSTM1 polymorphism (Madrigano et al., 2010). GSTP1 and GSTM1 polymorphisms 
have been associated with the biomarker of oxidative DNA-damage, 8-hydroxy-2’-
deoxyguanosine (Ren et al., 2010) and increased susceptibility to smoking-related CAD 




The high incidence of CAD in SA Indians in Durban was first reported in 1969 (Wainwright, 
1969) and decades later Indians in SA have the highest mortality for CAD (Norman et al., 
2006). The age of onset of CAD, in this ethnic group has decreased in the past decades. 
Recent studies show a strong familial link with the history of T2D hypertension and CAD, 
supporting a genetic basis for the development of the disease (Ranjith et al., 2004; Ranjith et 
al., 2005).  
 
In light of the evidence that variants of GSTP1 and GSTM1 influenced disease risk, this study 
aimed to assess the association of GST polymorphisms in young smoking and non-smoking 
SA Indian CAD patients. 
 
 
2.2 Materials and Methods 
 
Molecular grade reagents were purchased from Promega, United States, Fermentas, South 
Africa, Qiagen, United States and Biorad, SA, unless otherwise stated. All other reagents 
were purchased from Merck (SA).  
 
 
2.2.1 Patient recruitment 
 
One hundred and two CAD patients and 100 age, ethnicity and gender matched controls were 
enrolled in the study following institutional ethical approval (BE154/010). A full pathology 
report clinical markers was assessed by routine laboratory testing at the South African 
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National Accredited System Global Clinical and Viral Laboratory (Amanzimtoti, South Africa). 
The following parameters were tested: Haematology (Roche Sysmex 1800XT), Chemistry 
(Beckman Coulter DXC600), Endocrinology (Siemens Centaur XP), Serology (BD 
Biosciences FACS Calibur) as per international standards to obtain levels of total cholesterol, 
HDL, LDL, triglycerides, fasting glucose, 2h glucose, fasting insulin, glycosylated 
haemoglobin, sodium, potassium, bicarbonate, chloride, urea, creatinine, glomerular filtration 
rate, cell death (CD) 4 count, CD8 count, CD45 count and CD3 count. The physical 
measurements of weight, height, abdominal circumference, waist circumference and patient 
history were conducted by the clinician. The inclusion criterion for CAD patients were: Indian 
ancestry and unrelated, adults below the age of 45 years with stable CAD confirmed at 
angiography. The exclusion criteria for controls were: an acute coronary 
syndrome/revascularization procedure in the preceding 3 months, chronic renal or liver 
disease, malignancy and known active inflammatory or infectious disease.  
 
2.2.2 DNA isolation 
 
Genomic DNA was extracted from 300µl whole blood. A 1ml aliquot of 0.1M PBS (pH 7.4) 
was added to the whole blood. Tubes were inverted on a rotor for 10min and centrifuged (5 
000xg, 3min, room temperature (RT)). The supernatant was decanted and 1ml Tris-Cl (20mM, 
pH 8.0) solution was added to the pellet. The resuspended pellet was then inverted on a rotor 
for 10min and centrifuged (5 000xg, 3min, RT). The supernatant was discarded and 900µl of 
Tris-Cl (20mM, pH 8.0) solution was added to the pellet, inverted for 8min and centrifuged at 5 
000xg for 3min. The supernatant was decanted and 500µL lysis buffer (0.5%sodium dodecyl 
sulphate (SDS), 150mM NaCl, 10mM ethylenediaminetetraacetic acid (EDTA), 10mM Tris–
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HCl (pH 8.0) was added to the pellet of white blood cells. To this, RNase A (100µg/ml; 
DNase-free) was added and incubated (37°C, 1h). Subsequently, proteinase K (200µg/ml) 
was added and incubated (3h, 50°C) and a 0.1% volume 5mM potassium acetate was added 
before centrifugation (5 000xg; 15 min). Supernatants containing genomic DNA were 
transferred to fresh tubes, extracted with 100% isopropanol and washed with 70% ethanol. 
DNA samples were solubilised in 10mM Tris and 0.1mM EDTA (pH 7.4, 4°C). Concentrations 
of DNA were determined spectrophotometrically.  
 
2.2.3 Polymerase Chain Reaction  
The principle of PCR is based on the amplification of a segment of DNA using specifically 
designed primer pairs, DNA monomers, the enzyme DNA polymerase, the relevant co-factors 
(magnesium chloride (MgCl2)) and a DNA template. There are three major steps involved in 
the PCR amplification reaction viz. denaturation, annealing and extension under 




Figure 2.2 The polymerase chain reaction. 
DNA denaturation occurs at approximately 95oC during which double stranded DNA forms 
single stranded templates. The process of annealing involves the primer sets to anneal to the 
3’ ends of each DNA template, a process which occurs at a lower temperature (between 54oC 
and 60oC) and is dependent on the guanine and cytosine content of the primer sequence. The 
extension of DNA occurs at 72oC, the optimal temperature at which DNA polymerase (derived 
from Thermus aquaticus (Taq)) functions to extend the target DNA sequence from the 3’ end 
of the annealed primer (Ishmael and Stellato, 2008). 
  
 




To ascertain the effective concentrations required for an efficient and specific amplification 
process, optimization of the major components of the PCR mastermix was conducted. Briefly, 
the primer sets, MgCl2 and GoTaq DNA polymerase were titrated over a range of 
concentrations. Primer sets were optimised first by varying the concentrations between 20 
and 130 ρmol, while all other components were kept at a standard concentration. Once the 
PCR reactions were completed, they were verified by electrophoresis (150 V; 50 min) on a 
1.8% agarose gel containing 0.5 mg/ml ethidium bromide and visualized by UV light and 
digitally photographed using a gel documentation system (Uvitech Alliance 2.7). The reaction 
containing minimal primer dimers and a specific, pristine band of the expected size was 
selected. This concentration was then used in the next set of reactions where MgCl2 
concentrations were varied between 0.5 and 3.5 mM. This was then repeated for the Taq 
polymerase (0.5 and 1.1U). 
 
2.2.3.2 PCR-Restriction fragment length polymorphism  
  
A 176 base-pair PCR product was amplified using 15pmol of forward and reverse primers in a 
25μL reaction containing 200μM of each dNTP, 2.5mM MgCl2, 1XGreen GoTaq® Flexi buffer 
(Promega, United States), 0.5U GoTaq® DNA polymerase (Promega, United States) and 
100ng genomic DNA template. Primer sequences were:   
 Forward: 5’-ACCCCAGGGCTCTATGGGAA-3’; 




Following initial denaturation (96°C, 5min), amplification was carried out by 30 cycles of 
denaturation (96°C, 30s), annealing (55°C, 30s) and extension (72°C, 30s). This was followed 
by a final extension (72°C, 5min).  
 
Presence of the polymorphic restriction site was analyzed by restriction endonuclease 
digestion of the PCR amplicon. Restriction endonucleases cleave DNA at specific consensus 
sequences along the strand in order to determine the presence of the polymorphism (change 
in nucleotide base). The consensus sequences and cleavage sites for each enzyme is 
unique. 
 
Overnight digestion (37°C) was performed in 25μL (15μL PCR product, 4.5μL Buffer-R and 
0.5μL (5U) BsmAI (Fermentas, South Africa)). Amplicons homozygous for the G105 allele were 
completely digested and resulted in two restriction fragments (91bp and 85bp). Restriction 
fragments were electrophoresced on an agarose gel (3%, 0.5mg/ml ethidium bromide) and 
visualized (Appendix 6). 
 
2.2.3.3 Differential PCR 
 
To assess the GSTM1 polymorphism, a differential PCR was performed. Differential PCR is 
referred to as a semi-quantitative technique in which more than one gene is amplified in a 
single PCR reaction mixture. In this case, the co-amplification of a house-keeping gene, β-
globin, is necessary to prove the efficiency of the PCR reaction and an absence of the target 





 2.3 Schematic representing amplicons following differential polymerase chain 
reaction. 
 
Two PCR products (a 268 base-pair (β-globin) and 215 base-pair (GSTM1) product) were 
amplified using 30pmol of primers for the GSTM1 gene and 10pmol primers for the β-globin 
gene in a 25μL reaction (200μM each dNTP, 3.3mM MgCl2, 1XGreen GoTaq Flexi buffer, 1U 
Taq polymerase, 100ng genomic DNA template). Primer sequences were:  
 
 GSTM1   Forward: 5’-GAACTCCCTGAAAAGCTAAAGC-3’;  
      Reverse: 5’-GTTGGGCTCAAATATACGGTGG-3’ 
 β-globin   Forward: 5’-CAACTTCATCCACGTTCACC-3’;  
      Reverse: 5’-GAAGAGCCAAGGACAGGTAC-3’ 
 
Following initial denaturation (96°C, 5min) amplification was carried out by 25 cycles of 
denaturation (96°C, 30s), annealing (57°C, 30s), extension (72°C, 30s) and a final extension 
(72°C, 5min). Amplification products were electrophoresced on an agarose gel (4%, 0.5mg/ml 
ethidium bromide) and visualized. Presence of a 268bp product only is indicative of the 
homozygous null genotype. The amplification of a 215bp product is indicative of the presence 
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of the gene in either a homozygous positive for the presence of the gene or heterozygote 
state.  
 
2.2.4 Statistical Analysis 
 
Hardy-Weinberg statistics were calculated to assess the distribution of genotypes in our 
sample population. Graphpad Prism Software was used for the Fisher’s exact test to assess 
the contingency of alleles. The D’Agostino and Pearson normality tested column statistics 








All clinical parameters assessed were similar between the groups with the exception of 
hypertension, with a larger percentage of patients presenting with higher systolic/diastolic 
pressure (Table 2.1). Single nucleotide changes at codon105 of the GSTP1 gene were 
investigated using RFLP-PCR. The genotype frequencies observed did not deviate from those 
predicted by Hardy-Weinberg statistics (GSTP1: p=0.294, CAD patients, p=0.413 controls; 
GSTM1 p=0.083, CAD patients, p=0.64; chi-square test).  
 







(n=102) p value 
Age (years)                                   37±4.31                    37±4.45                     0.953                  
BMI (kg/m2)                                   27.8±0.5                   27.93±0.4                  0.888 
Hypertensive  (%)                            22 (22)                    44 (43)                      0.0016* 
Diabetic (%)                                     39 (39)                     59 (58)                     0.982   
Total Cholesterol (mmol/L)      5.41±0.101                 5.37±0.182                    0.537 
LDL (mmol/L)                           3.70±0.091                 3.39±0.170                    0.104  
HDL (mmol/L)                          0.96±0.031                 0.93±0.027                    0.414 
Triglycerides (mmol/L)             1.90±0.184                 2.26±0.137                    0.115 
Clinical parameters represented as mean ± standard error of the mean. *P<0.01 
 
A significant skew toward the A105/A105 genotype was observed in CAD patients with a higher 
frequency compared to controls. In the control group the homozygous A105/A105 and 
heterozygous A105/G105 genotypes were observed at frequencies of 48% and 45%, 
respectively. The frequency of the A105 allele was significantly higher in CAD patients (80% 
vs. 70.5%; odds ratio=0.6011 95% CI=0.3803-0.9503, p=0.0377; Table 2.2). The GSTM1 0/0 
genotype was also significantly more frequent in CAD patients (36% vs. 18%; odds 
ratio=2.593, p=0.0043; Table 2.3). 
 
Table 2.2: Genotype and Allelotype GSTP1 frequency in CAD patients and controls 
 Control,  n (%) CAD patients, n(%) p value 
Genotype frequency                                                                                                0.797# 
GSTP1 A105/A105 48 (48) 66 (65)  
GSTP1 A105/G105 45 (45) 31 (30)  
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GSTP1 G105/G105 7 (7) 5 (5)  
Allelotype frequency                                                                                                 0.0377 
          GSTP1 A105 141 (70.5) 163 (80)  
          GSTP1 G105 59 (29.5)  41 (20)  
# Chi-square test for heterogeneity between CAD patient and control genotype distribution. 
Chi-square statistic =  0.587, 1 degree of freedom.  
 
Since a higher frequency of the GSTP1 A105 and GSTM1 null alleles were observed in 
patients, this study investigated whether there were genotypic differences in relative CAD risk 
with respect to these loci. Table 2.2 shows that the presence of the GSTP1 A105 and GSTM1 
null genotype confers a significant risk for CAD. The groups were then stratified according to 
smoking history and the number of smokers in the patient group was much higher than the 
controls and significant association between smoking and CAD was found (p<0.0001, odds 
ratio=0.2245, 95% CI=0.1062-0.4746). 
 
Table 2.3: Genotypic frequency of GSTM1 in CAD patients and controls 
 Control, n (%) CAD patients, n (%) p value 
Genotype  frequency                                                                                                                           0.83
# 
GSTM1 +/+ or +/0 82 (82) 65 (64)  
GSTM1 0/0 18 (18) 37 (36) 0.0043 
#Chi-square test for heterogeneity between CAD patients and controls allele frequency. Chi-
square statistic = 4.463, 1 degree of freedom. 
 
The majority of patients who smoked presented with the GSTP1 A/A genotype (p=0.0987, 
odds ratio=0.5667 95% CI=0.2952-1.088; Table 2.4) and the GSTM1 0/0 (p=0.0221, odds 
ratio=2.386 95% CI=1.137-5.009; Table 2.4). Taken together the data shows that there is a 
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higher relative risk of CAD associated with GSTP1 A105/A105 and GSTM1 null genotypes and 
this risk is increased with smoking.  
 
Table 2.4: Summary of smokers stratified by genotypes for CAD risk identification  
 Control, n (%) CAD patients, n (%)  
Non-smokers 35 (35) 11 (10) p<0.0001 
aRR=1.826 
b95% CI(1.427-2.336) 
Smokers/Ex-smokers 65 (65) 91 (90) 
Smokers/Ex-smokers  
GSTP1 A105/G105 & G105/G105 
31 (31) 31 (30) 
p=0.0987 
RR=1.382 
95% CI(0.958-1.994) GSTP1 A105/A105 34 (34) 60 (59) 
Smokers/Ex-smokers 
GSTM1 +/+ & +/0 
52 (52) 57 (56) 
p=0.0221 
RR=1.725 
95% CI(1.044-2.851) GSTM1 0/0 13 (13) 34 (33) 




The pathogenic processes of atherosclerosis and thrombosis leading to the development of 
CAD are closely related to genetic and environmental influences.  
 
The INTERHEART study placed smoking second on the list of risk factors for myocardial 
infarctions (OR: 2.87, 99% CI) (Yusuf et al., 2004). The Systemic Coronary Risk Evaluation 
project also estimated the 10-year fatal cardiovascular risk to be twice as high for smokers vs. 
non-smokers for any given age, systolic blood pressure and cholesterol level (Conroy et al., 
2003). The number of smokers worldwide is expected to reach 1.7 billion by 2025 (Mathers 
and Loncar, 2006; World Health Organisation, 2012). According to the World Health 
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Organisation, smoking related deaths is expected to rise from 4.8 million in the year 2000 to 8 
million in 2030 if current trends are maintained.  
 
Endothelial cell damage in vasculature is caused by changes in haemodynamics and 
oxidative stress, leading to thrombosis and atherosclerosis. The continuous cycle of 
inflammation from atherosclerotic plaques and arterial wall lesions contributes to elevated 
levels of CRP in CAD patients. The low grade inflammation, recruitment and activation of 
leucocytes to the atherosclerotic lesion plays an important role in the generation of ROS and 
RNS derived from the myeloperoxidase system and macrophage respiratory burst in an 
attempt to circumvent the spread of foreign material, while simultaneously exposing 
biomolecules to oxidative stress (Hulsmans and Holvoet, 2009).   
 
The data in this study shows an association of the GSTP1 wild-type variant A105 and the 
GSTM1 0/0 with CAD. GST acts as a general base catalyst by increasing the rate of GSH 
conjugation to hydrophobic substrates by deprotonation of GSH to GS- by an active 
tyrosinase. The change in codon105 of the GST gene causes an amino acid substitution from 
Ile to Val, resulting in a change in enzyme activity. Two previous studies showed the change 
from Ile to Val caused deviations in the atomic coordinates of the side chain of the key H-site 
residues that affected the enzyme’s catalytic activity and increased susceptibility to smoking-
related CAD (Palmer et al., 2003; Park et al., 2004; Singh et al., 2011). Earlier literature, 
however, indicates a 7-times more active conjugation of GSTP1 with the Val variant to diol 




These observations suggest the presence of the GSTP1 G allele in healthy controls enhances 
the efficacy of antioxidant mechanisms. The null GSTM1 genotype, however, results in the 
complete absence of that specific isoform of the enzyme, hence affecting the detoxification 
capacity. The strong association of the null genotype in CAD patients indicates a key role of 




The association between smoking and CAD seen in this cohort is in agreement with previous 
studies (Palmer et al., 2003; Park et al., 2004; Singh et al., 2011). The high percentage of 
patients who smoked and presented with the GSTP1 A105/A105 and GSTM1 0/0 genotypes 







THE ROLE OF UNCOUPLING PROTEIN 2 -866 G/A AND UNCOUPLING PROTEIN 3 -55 







Uncoupling proteins are members of the super family of anion carrier proteins present in the 
inner mt membrane. The roles of UCPs 2 and 3 are not clearly defined but have been linked 
in the protection against oxidative damage; ageing and degenerative diseases (Affourtit et al., 
2007). They regulate the mt membrane potential by the discharge of the proton gradient 
generated during oxidative phosphorylation and negatively regulate mt ATP synthesis. UCP2 
and UCP3 can reduce the production of superoxide radicals at complex I, II and III of the mt 
respiratory chain by reducing the electrical potential across the inner mt membrane 
(Laskowski and Russell, 2008).  
 
The function of UCP2 and UCP3 is dependent on specific activators such as hydroxynonenal, 
a by-product of phospholipid peroxidation, as well as fatty acids (FAs) (Echtay et al., 2003; 
Rial et al., 2004). Once activated, UCP2 and UCP3 increase the net proton conductance and 
the export of fatty acids and other anions from the mt matrix (Figure 3.1) (Brand and Esteves, 
2005). In pancreatic beta cells, UCPs are thought to regulate insulin secretion by discharge of 
the proton motive force, decreasing ATP production and accumulation of ADP in the 





Figure 3.1 A model of the physiological functions catalyzed by UCP2 and UCP3. The 
complexes (I, III and IV) of the electron transport chain on the inner mitochondrial (mt) 
membrane transfers protons (H+) from reducing equivalents (NADH, FADH2) in the mt 
matrix into the intermembrane space creating a proton gradient for the synthesis. 
Protons are pumped back into the mt membrane space by ATPase, uncoupling 
proteins (UCPs) or via an ATP dependant anion transporter (ANT). Electron leakage 
from the electron transport chain reacts with molecular oxygen to form reactive oxygen 





In Figure 3.1, the double purple structures represent the inner and outer mt membrane. FAs 
are converted to fatty acyl CoA in the matrix, then reducing equivalents (H+) are removed by 
β-oxidation and passed to the electron transport chain (Complexes I, II, III & IV represented 
by yellow boxes) where they are oxidized, causing proton pumping into the inter-membrane 
space. The resultant proton motive force drives ATP synthesis (at ATP synthase) or is 
dissipated by UCPs.  During ROS production, UCPs are activated which lower the proton 
motive force to protect the cell against oxidative stress (Echtay et al., 2003). Another function 
of UCPs is to export FA anions generated when FA CoA is hydrolyzed and CoA is released 
for β-oxidation of FA (Rial et al., 2004). If ROS induces peroxidation of membrane 
phospholipids forming FA peroxide anions, these may also be exported by UCPs.  
 
The role of UCPs in regulating oxidant stress and implications with respect to the 
pathogenesis of heart failure was reviewed (Laskowski and Russell, 2008). UCP2 in 
macrophages is necessary for efficient mt oxidation of glutamine, a strong inducer of UCP2 
expression (Hurtaud et al., 2007; Nubel et al., 2008). It was also shown that UCP2 increased 
FA oxidation and promoted the metabolic shift from glucose oxidation to FA oxidation in 
mouse embryonic fibroblasts (Pecqueur et al., 2008). Several studies showed that UCP2- and 
UCP3-deficient mice overproduce ROS and hyper-secrete insulin (Vidal-Puig et al., 2000; 
Zhang et al., 2001; Brand et al., 2002; Blanc et al., 2003). Other studies have linked UCPs 
with disease prevalence such as diabetes (Xu et al., 2011) and obesity (Salopuro et al., 
2009), the major predisposing factors leading to the development of CAD.   
 
Compromised mt function, especially skeletal muscle FA oxidation, leads to increased 
triglyceride synthesis and ectopic lipid deposits (Roberts and Sindhu, 2009; Rogge, 2009). 
50 
 
The accumulation of cellular triglycerides has been implicated in increased lipid peroxidation, 
nitric oxide synthase (NOS) activity and pro-inflammatory cytokine production due to oxidative 
stress (Roberts and Sindhu, 2009). Furthermore, oxidative stress has emerged as the 
underlying mechanism for pathology in T2D and CAD. The distribution of UCP SNPs has 
been identified in several ethnic groups at different frequencies (Xu et al., 2011). 
 
A few studies assessed the UCP2 -866 G/A SNP (located in the cis-regulatory site of the 
promoter region) and the UCP3 -55 C/T SNP (located 6 base-pairs upstream from the TATA 
box in the core promoter region) and found a functional link with CAD severity, progression 
and occurrence (Salopuro et al., 2009; Srivastava et al., 2010). In a group of diabetic patients 
there was a significant association of CRP levels with the UCP2 -866G/A SNP (Lapice et al., 
2010). 
 
The aim of this study was to explore the relationship between UCP2 -866G/A and -UCP3 
55C/T SNPs and the risk of CAD in young SA Indians. 
  
3.2 Materials and Methods 
 
3.2.1 Patient recruitment 
 
As described in Section 2.2.1. 
  








Evaluation of SNPs in the UCP2 -866(G/A) (rs659366) and the UCP3 -55(C/T) (rs1800849) 
promoter region was done using PCR-RFLP. The UCP2 promoter region was amplified using 
10pmol of primers: 
                   Forward:  5’CACGCTGCTTCTGCCAGGAC’3  
                   Reverse:  5’AGGCGTCAGGAGATGGACCG’3, 
resulting in a 363bp PCR product.  
The UCP3 region was amplified using 20pmol of primers: 
                   Forward:   5’GGATAAGGTTTCAGGTCAGGC’3 
                   Reverse:  5’AAGGGATGAGGGAGGAGAA’3, 
resulting in a 194bp PCR product.  
 
The PCR reaction volume for each sample was 40µL, comprising of: GoTaq® Flexi Buffer, 
25mM MgCl2, 200µM of each dNTP, 0.5U Taq polymerase (Promega, United States), and 
10ng genomic DNA template. Amplification conditions: initial denaturation (95°C, 5min), 
followed by 35 cycles of denaturation (95°C, 30 sec), annealing (UCP2: 68°C and UCP3: 
54°C) for 30 sec and extension (72°C, 30 sec). Final extension was achieved at 72°C for 7 
min.  
 
Following PCR, the amplicons were subjected to cleavage by restriction enzymes to 
determine the presence of polymorphisms at the designated sites. For digestion, a 31µL 
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reaction volume containing 10µL of PCR amplicon, 1µL specific RE and 2µL appropriate 
buffer as specified by the manufacturer (Fermentas, South Africa) was prepared. Digestion 
proceeded for 16 h at 37°C.   Restriction products were analyzed on a 3% agarose gel 
stained with 0.5mg/ml ethidium bromide and visualized under UV light. Mlu I was used to 





















Clinical and laboratory parameters were measured in CAD patients and controls (See Table 
2.1 in Section 2.3.1). 
 
Single nucleotide changes at positions -866 in the UCP2 and -55 in the UCP3 promoter 
regions were investigated using RFLP-PCR. The genotype frequencies for UCP2 -866G/A 
and UCP3 -55C/T polymorphism observed did not deviate with those predicted by Hardy-
Weinberg statistics (UCP2: p=0.319 controls, chi-square statistic=0.99; p=0.8487, chi-square 
statistic=0.036 CAD patients; UCP3: p=0.16 controls, chi-square statistic=1.984; p=1, chi-
square statistic=0.0005 CAD patients).  
 
 
Table 3.1: Frequency of genotypes and allelotypes in control and CAD patients 
            
 
  












AA 35 29   
 AG 52 59   
 GG 13 12   
 A 40 42 
1.110 (0.744-1.655) 
 






CC 63 66   
 CT 30 32   
 TT 7 2   
 C 78 82 
0.788 (0.482-1.289) 
 
 T 22 18  
       
 
No significant association between UCP2 -866G/A and UCP3 -55C/T genotypes was 
observed in CAD patients compared to controls (Table 3.1). For the UCP2 -866G/A SNP 
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(control group) the homozygous GG, AA and heterozygous GA genotypes were observed at 
frequencies of 13%, 35% and 52%, respectively compared to cases with 12%, 29% and 59%, 
respectively (Table 3.1).  The homozygous CC and TT genotypes were observed at 63% vs. 
66% and 7% vs. 2% between controls and CAD patients, respectively, with C/T presenting at 
30% in controls and 32% in patients.  
 
Table 3.2: Summary of elevated laboratory parameters in CAD patients stratified by -
866G/A UCP2 and -55C/T 










UCP2      
-866 
AA 2.04±0.43 6.31±0.54 6.31±0.54 4.43±0.79  
 AG 2.53±0.23 6.06±0.36 6.48±0.26 10.1±1.93  
 GG 2.15±0.19 6.66±0.54 6.76±0.36 5.45±0.10  
 
UCP3      
-55 
CC 2.33±0.17 6.11±0.27 6.44±0.21 8.13±1.47  
 CT 2.06±0.25 6.48±0.57 6.76±0.35 7.44±1.09  
 TT 6.47±1.70*# 11.87±3.74*# 10.1±2.57*# 10.23±4.14  
        
Parameters represented as mean (standard error of the mean) P<0.05compared to -55UCP3 
CC*or CT#  
 
When comparing the presence of elevated fasting glucose, HbA1c and triglyceride levels in 
relation to the UCP2 -866 AA, AG and GG genotypes and UCP3 -55CC, CT and TT 
genotypes, a significantly higher level of fasting glucose (p=0.0006), HbA1c (p=0.0025) and 
triglycerides (p<0.0001) in patients with the UCP3 -55 TT genotype was observed (Table 3.2). 






3.3 Discussion  
 
This study showed that no correlation between SNPs in the -866G/A UCP2 and -55C/T UCP3 
promoter region and CAD in young South Africans of Indian descent but stratification of 
clinical parameters such as triglycerides, fasting glucose and percentage HbA1c, higher in 
CAD patients, was elevated in the presence of the UCP3 -55T/T genotype. A larger sample 
size in this genotypic group, however, is required to make meaningful conclusions. 
 
Inflammation plays an integral role in initiation, progression and rupture of atherosclerotic 
plaques, and CRP is widely recognized as a marker for CVD (Hulsmans and Holvoet, 2009; 
Kengne et al., 2011). Oxidative stress, another major contributing factor to chronic 
inflammation, is prominent in atherosclerotic plaques. The regulatory function of UCPs in ROS 
generation has important implications for a role in inflammation (Palmer et al., 2009).  
 
The UCP2 -866G/A polymorphism has been associated with CAD and T2D in several 
population groups (Salopuro et al., 2009; Srivastava et al., 2010). The overproduction of ROS 
and hyper-secretion of insulin in UCP2- and UCP3-deficient mice models indicated a 
functional role of UCPs in the development of T2D (Zhang et al., 2001). Recent meta-analysis 
on the UCP2 -866 and UCP3 -55 SNPs in Indian subjects with T2D or obesity was conducted 
(Dalgaard, 2011; Xu et al., 2011). The UCP2 -866 A allele was associated with increased risk 
of obesity and hyperinsulinaemia between 200 patients and 290 controls (Srivastava et al., 
2010); a lack of association of UCP2 -866 and reduced risk UCP -55 with diabetics (n=487) 
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compared to controls (n=385) (Vimaleswaran et al., 2011); and an association of the UCP2 -
866 G allele with diabetes mellitus (n=762 vs. controls n=924) (Gable et al., 2006).  
 
The UCP3-55 T allele was shown previously to increase the onset of T2D in middle-aged men 
(Gable et al., 2006), was associated with abdominal fat distribution (Cassell et al., 1999) and 
obesity (Otabe et al., 2000; Halsall et al., 2001). The influence of UCP3-55T/T genotype on 
clinical markers of obesity and T2D is an important finding based on the premise that T2D and 
obesity are predisposing factors for CAD development.  
  
A significantly high number of CAD patients were overweight with a mean BMI of 27.93kg/m2. 
This is important as adipose tissue, and the macrophages found within, is a source of IL-6 
and adipokines that contribute to atherosclerosis. Based on an immune-modulatory role of 
UCP2 due to its expression in macrophages and T cells, Lapice et al. (2010) reported a 
significant association of elevated hsCRP levels with the UCP2 -866 GG genotype (Lapice et 
al., 2010). Elevated levels of pro-inflammatory cytokines are found in inflammatory disease 
conditions (Murray and Freeman, 2003). This is evident in CAD patients with higher levels of 
CRP, its levels are not susceptible to circadian variation (Szalai et al., 2005) and its plasma 
half-life of 19h is nearly constant between normal subjects and patients with inflammatory 
conditions (Otabe et al., 2000).  
 
In the present study, hsCRP levels were elevated in CAD patients presenting with the UCP2 -
866 homozygous G genotype as well as the UCP3 -55 homozygous T genotype supporting 
the hypothesis of increased ROS activating nuclear factor kappa B (NF-K B) pathway which 




The association of UCP2 polymorphisms with disease risk has been addressed in several 
studies. However, the genetic studies on polymorphisms on CAD, especially in Indians in SA 
are limited. Genetic association studies provide a potentially powerful tool for identifying 
genetic variations that influence susceptibility to common diseases. It is well-known that 
ethnicity is one of the most important factors for evaluating genetic effects on common 




The presence of the UCP -866 G/A and UCP -55 C/T SNPs does not directly influence CAD 
susceptibility in SA Indians. The association between UCP3 -55T/T genotype with elevated 
triglycerides, fasting glucose, HbA1c and CRP is in agreement with other studies (Lapice et 













PROMOTOR POLYMORPHISMS IN THE INTERLEUKIN-6 (-174 G/C) AND C-REACTIVE 





Pro-inflammatory factors play a major role in the development of CAD, and elevated levels 
are used as diagnostic markers and risk factors (Pearson et al., 2003; Lubrano et al., 2009). 
Interleukin 6, a pro-inflammatory cytokine, has recently become a focus of interest in CAD 
development and is produced by an array of immune cells including activated macrophages, 
lymphocytes and endothelial cells (Figure 4.1) (Yudkin et al., 2000; Lubrano et al., 2009).  
 
Interleukin 6 is one of the principle mediators of the hepatic acute phase response due to its 
ability to promote inflammation through the activation and proliferation of lymphocytes, 
differentiation of B cells and recruitment of immune cells (Stenvinkel et al., 2005). Adipose 
tissue is considered as one of the most significant sources of IL-6 due to stimulation from 
adipokines. It is for this reason that obesity is linked to low grade inflammation as a potential 




Figure 4.1 Interleukin 6 is produced from a range of cell types and also has several 
targets (Schuett et al., 2009). 
 
C-reactive protein expression is primarily induced by IL-6 and synergistically enhanced by IL-
1β and to a lesser extent by TNF-α (Rhodes et al., 2011). The biological roles of CRP are 
attributed to its ligand binding properties, functional in the clearance of apoptotic, damaged 
host cells as well as pathogenic agents such as bacteria via the formation of immune 
complexes as illustrated in Fig. 4.2, thus contributing to inflammation.  
 
The baseline level of CRP amongst individuals varies by up to 40% due to genetic factors 
(Hage and Szalai, 2007; Cordeiro et al., 2008). As a result, there is a prominent individual-





Figure 4.2 CRP synthesized in response to pro-inflammatory cytokines is released into 
circulation and interacts with several target molecules (Rhodes et al., 2011). 
 
Single nucleotide polymorphisms in the promoter regions of the genes of inflammatory 
cytokines have been shown to influence mRNA and cytokine levels in circulation and are 
implicated in the development and progression of inflammatory conditions (Olivieri et al., 
2002; Hage and Szalai, 2007; Shanker and Kakkar, 2010; Yeh et al., 2010; Najar et al., 2011; 
Pereira et al., 2011). The promoter region of IL-6 is very sensitive to environmental stress (as 
a result of oxidative stress, hypoxia or inflammation activated molecules such as the mitogen 
activated protein kinases - JNK and p38 - both of which have recently been targeted by 
therapeutics to reduce inflammation) and is thought to be highly conserved in the regions 
susceptible to transcription factor binding (Schuett et al., 2009). The IL-6 SNP at position 174 
in the promoter region is of particular importance in chronic inflammatory diseases (Fishman 




The IL-6 gene is located at chromosome 7 position p21, (Ray et al., 1990; Kiszel et al., 2007). 
The IL-6 -174 SNP is situated near a transcription factor ‘hotspot area’ that is closely related 
to transcriptional regulation of IL-6 (Ray et al., 1990). Another important factor is the that two 
multiple responsive elements as well as additional transcription factor binding sites, namely 
cyclic adenosine monophosphate responsive element (CRE) and cytidine-cytidine-adenine-
adenine-thymine (CCAAT)/enhancer binding sites, lie in the IL-6 gene region between 
positions -173 and -145. It has therefore been speculated that a single nucleotide change at 
position -174 may interfere with transcription factor binding in a positive or negative manner. 
This has been observed in several population genetic studies which revealed conflicting 
results on IL-6 production and the presence of the SNP (Fishman et al., 1998; Brull et al., 
2001; Sie et al., 2006). 
 
Several studies have assessed the IL-6 -174 G/C promoter polymorphism in different 
populations, including subjects of Indian ethnicity. The presence of the SNP was observed at 
varying frequencies in these populations (Vickers et al., 2002; Ivanova et al., 2011; Ujcic-
Voortman et al., 2011). A recent meta-analysis study on Caucasian, Turkish, Tunisian and 
Chinese populations with CAD showed a high frequency of the IL-6 -174 GC genotype 
compared to the CC genotype with only a few studies showing different outcomes (Niu et al., 
2012).  A study on Indians (from India) showed a high frequency of GG genotypes with higher 
frequencies of the G allele (Maitra et al., 2008). To date, however, no studies have 
investigated the distribution of this SNP in the SA population.  
 
Single nucleotide polymorphisms in the promoter region of CRP have been shown to 
influence circulating levels of CRP and are strongly associated with inflammatory conditions 
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(Hage and Szalai, 2007; Shanker and Kakkar, 2010; Najar et al., 2011). Distribution of SNPs 
in the CRP gene and promoter region have been identified in various ethnic groups (Vickers 
et al., 2002; Szalai et al., 2005; Hage and Szalai, 2007; Paik et al., 2007; Ivanova et al., 2011; 
Ujcic-Voortman et al., 2011).  
 
The influence of promoter SNPs on gene expression and protein levels has been observed in 
several studies (Carlson et al., 2005; Miller et al., 2005; Szalai et al., 2005). A recent study on 
a group of diabetic North Indians found that the rs3093059 CRP polymorphism is a cis-acting 
contributor to the variance in hsCRP levels (Mahajan et al., 2011).   
 
Promoter polymorphisms in the CRP gene have been assessed. One such study evaluated 
the bi-allelic SNP at position -409 and tri-allelic SNP at position -390 resides within the 
sequences -412CACGTG-407 (E-box 1) and -394CACTTG-389 (E-box 2) respectively (Szalai 
et al., 2005). The SNP at position -390 is interesting as the nucleotide cytosine can either be 
replaced with adenine or thymine. The A allele has been observed at very low frequencies. 
Both E-box 1 and E-box 2 contain DNA sequences that support transcription factor (such as 
upstream stimulatory factor-1) binding. In the presence of the -409 G-allele and the -390 T-
allele, transcription factor binding is enhanced (Szalai et al., 2005). 
 
In this study the frequency of promoter polymorphisms in IL-6 (-174G/C) and CRP (-
390C/A/T) genes of young SA Indian CAD patients was evaluated. In addition, the effect of 





4.2 Materials and Methods 
 
4.2.1 Patient recruitment 
As described in Section 2.2.1. 
  
4.2.2 DNA isolation 




Evaluation of SNP at position 174 in the IL-6 promoter region (G/C) (rs1800795) and the tri-
allelic SNP in the CRP promoter region (-390 C/A/T) was done using PCR-RFLP. The IL-6 
and CRP promoter region was amplified using 40pmol of both forward and reverse primers. 
PCR reaction volume for each sample was 40µl, comprising of: GoTaq® Flexi Buffer, 25mM 
MgCl2, 200µM of each dNTP, 0.5U GoTaq®DNA polymerase (Promega, United States), and 
10ng genomic DNA template. Amplification conditions: initial denaturation (95°C, 5min), 
followed by 35 cycles of denaturation (95°C, 30s), annealing (55°C, 30s) and extension (72°C, 
30s). Final extension was achieved at 72°C for 7 minutes.   
The following primers were used:  
 IL-6   Forward: 5’TGACTTCAGCTTTACTCTTTG3’;  
 IL-6   Reverse: 5’CTGATTGGAAACCTTATTAAG3’ 
 CRP Forward: 5’AAGGGGTTAGTGATAATGTCC3’ 




The PCR amplified a 168bp product of the IL-6 promoter region and 141bp product of the 
CRP promoter region. DNA bands were visualized by UV light and captured using a gel 
documentation system (Uvitech Alliance 2.7). To determine the -174G/C genotype, the PCR 
product was restricted with the restriction enzyme Nla III (5u/µl) (Fermentas, South Africa), 
which cuts in the presence of the -174 C-allele, resulting in two fragments of 119bp and a 
smaller fragment (migrates off the gel). No cleavage occurs in the presence of the -174 G-
allele. For the tri-allelic SNP, Bfa I and Taq I restriction enzymes were used to detect the CRP 
-390 SNP. Note that provision for Taq I restriction site was made by the underlined nucleotide 
in the reverse primer, which indicates the mismatch (T/A) (Appendix 6).   
 
 
4.2.4 IL-6 Enzyme-linked immunosorbent assay (ELISA) 
 
Human IL-6 ELISA Kit II (BD OptEIA™, Figure 4.3) was used to measure the IL-6 serum 
levels of patients and controls. As per user manual, ELISA diluent (12ml buffered protein 
base, 0.09% sodium azide) was added into a 96 well microtitre plate coated with anti-human 
IL-6 monoclonal antibody. A serial two fold dilution ranging from 0pg/ml to 250pg/ml was 
prepared. Standards and samples were added into appropriate wells. Following incubation 
(2h, RT) wells were rinsed with wash buffer (1× detergent solution with ProClin™-150). 
Working detector (containing Streptavidin-horseradish peroxide and Biotinylated anti-human 
IL-6 monoclonal antibody) was added into each well and incubated (1h, RT, dark). Wells were 
rinsed with wash buffer, seven times, followed by the addition of TMB One-Step Substrate 
Reagent (3,3’,5,5’-tetramethylbenzidine) and incubated (30min, RT, dark). Following 
incubation, stop solution (1M phosphoric acid) was added, and absorbance measured at 
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450nm (reference: 570nm) with a microplate reader (Bio-Tek µQuant, United States). Serum 
concentrations of IL-6 were calculated by extrapolation from the standard curve (Appendix 1). 
 
 















The single nucleotide change at positions -174 in the IL-6 promoter region and -390 in the 
CRP promoter region was investigated using PCR-RFLP.  
 
Table 4.1 Frequency of genotypes and alleles in IC, CAD, non-diabetic IC and CAD. 
IC CAD
OR            
(95% CI)
IC            
(non T2D)
CAD          
(non T2D)
OR               
(95% CI)
Genotype frequency
 GG 58 67 34 29
GC 32 27 19 11
CC 10 6 8 1
Allelotype frequency
 G 148 161 87 69
C 52 39 35 13
Genotype frequency
 AC 3 3 3 2
AT 7 4 5 2
CC 56 74 29 30
CT 24 9 15 5
TT 10 10 9 2
Allelotype frequency
 C 139 160 78 67
A/T 61 40 46 15
1.307            
(1.047-1.632)
0.689            
(0.430-1.105)
 CRP             
-390 
C/A/T
IL-6               
-174   
G/C
1.755              
(1.090-2.778)
2.634             
(1.350-5.138)
 
Fischer’s exact test for heterogeneity between alleles of the IL-6 -174G/C SNP where p=0.152 
for Indian control (IC) vs. CAD; and p=0.0431 for Control and CAD patients who were not 
diabetic (non T2D). Fischer’s exact test for heterogeneity between alleles of the CRP -
390C/A/T SNP where p=0.0211 for IC vs. CAD; and p=0.0048 for non T2D IC and non T2D 
CAD patients. (Percentages not shown as n=100 for each group). 
 
The genotypic frequencies for the -174 IL-6 G/A polymorphism conform to the Hardy-
Weinberg equilibrium (IC: Χ2=2.84, p=0.09; CAD: Χ2=1.96, p=0.16, Table 4.1). No association 
was found between CAD and the IL-6 -174G/A SNP (p=0.152, OR: 1.54 95% CI: 0.905-
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2.324). A high percentage of the IC (39%) and CAD patients (59%) were pre-diabetic/ 
diabetic.  We assessed genotypic frequencies between the IC and CAD following exclusion of 
diabetic subjects in each group and found a weak association of the IL-6 -174 G allele with 
CAD (p=0.0431, OR: 2.135 95% CI: 1.049-4.347). Interestingly, the non-diabetic IC presented 
with a significantly higher frequency of the C allele (71% -G vs. 29% -C) compared to non-
diabetic CAD patients (84% -G vs. 16% -C; Table 4.1).  
 
For the tri-allelic -390 C/A/T CRP polymorphism, the control group presented with 56% and 
10% homozygous CC and TT genotypes and 7%, 3% and 24% heterozygous AT, AC and CT 
genotypes, respectively. The frequency of -390 CRP genotypes in CAD patients were 4% AT, 
3% AC, 74% CC, 9% CT and 10% TT (Table 4.2). A weak association (p=0.0211, OR 1.299 
95% CI: 1.064-1.586) with CRP -390 C allele and CAD patients was observed compared to 
controls (Table 4.1). This strength of the association, however, increased (p=0.0048, OR 
2.634 95% CI: 1.350-5.138) when diabetic subjects were excluded from the analysis of both 
the IC and CAD groups (Table 4.1).  
 
The levels of IL-6 and CRP between IC and CAD patient groups and non-diabetic IC with non-
diabetic CAD patients were then compared (Table 4.2). The median levels of IL-6 were similar 
in CAD patients and non-diabetic CAD patients compared to respective control groups. CRP 
levels were higher in CAD patients and non-diabetic CAD patients compared to respective 






Table 4.2 IL-6 and CRP levels between IC, CAD, non-diabetic IC and CAD groups. 
p value p value
IC 0.9 (0.87, 0.92) 2.9 (1.93, 8.35)
CAD 0.9 (0.90, 0.91) 5.65 (1.9, 8.2)
IC (non-T2D) 0.9 (0.74, 0.91) 2.4 (1.90, 7.80)
CAD (non-T2D) 0.9 (0.90, 0.91) 6.0 (1.9, 9.4)




 Data represented as the median (25th percentiles, 75th percentiles). 
 
Table 4.3 IL-6 and CRP in IC, CAD, non-diabetic IC and CAD stratified according to 
homozygous wild-type and variants of the IL-6 -174G/A polymorphism. 
p value p value
GG 0.9 (0.90, 1.78) 3.2 (1.9, 7.65)
GC/CC 0.9 (0.64, 0.91) 2.8 (2.0, 9.50)
GG 0.9 (0.90, 0.91) 5.8 (1.90, 8.5)
GC/CC 0.9 (0.90, 0.92) 5.4 (1.87, 6.8)
GG 0.9 (0.9, 4.295) 2.2 (1.8, 7.35)
GC/CC 0.75 (0.64, 0.9) 2.8 (2.0, 9.50)
GG 0.9 (0.90, 0.91) 7.4 (1.9, 10.45)








IC                  
(non-T2D)
CAD           
(non-T2D)





ap<0.05 IL-6 levels higher in the GG group than the GC/CC group in IC, bp<0.05 IL-6 levels 
higher in the homozygous G group than the GC/CC group in non-diabetic Indian controls (IC).  
Data represented as the median (25th percentiles, 75th percentiles). 
 
IL-6 levels were then stratified according to the homozygous wild-type genotypes of the IL-6 -
174G/C and CRP -390C/A/T polymorphisms and a combined group of the variant alleles 
(Table 4.3, Table 4.4). 
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Table 4.4 Levels of IL-6 and CRP between IC, CAD patients, and non-diabetic IC and 
CAD patient stratified according to homozygous wild-type and variants of the CRP  -
390C/A/T polymorphism. 
p value p value
CC 0.9 (0.90, 0.95) 5.0 (1.9, 7.78)
AC/AT/CT/TT 0.9 (0.69, 0.91) 2.5 (2.03, 8.88)
CC 0.9 (0.9, 0.91) 5.5 (1.89, 7.83)
AC/AT/CT/TT 0.9 (0.9, 0.91) 6.3 (2.34, 9.35)
CC 0.9 (0.89, 0.92) 2.4 (1.85, 7.75)
AC/AT/CT/TT 0.9 (0.70, 0.92) 2.75 (2.0, 7.88)
CC 0.9 (0.9, 0.913) 5.8 (1.89, 8.85)
AC/AT/CT/TT 0.9 (0.87, 0.91) 7.4 (5.2, 9.8)













ap<0.05 IL-6 levels significantly higher in the CC group than the group of combined variant 
alleles in indian controls (IC)  (Mann-Whitney Test).  Data represented as the median (25th 
percentiles, 75th percentiles). 
 
A consistent trend amongst the control and CAD groups was observed. The group of subjects 
that presented with the homozygous IL-6 -174 GG and those which had the CRP-390 CC 











Modification and entry of LDL into the endothelium promotes an inflammatory response to 
vascular injury (Schuett et al., 2009). This stimulates the recruitment of inflammatory cells 
such as monocyte-derived macrophages and lymphocytes, and subsequent release of pro-
inflammatory cytokines. Both CRP and IL-6 are implicated in the pathogenesis of 
atherogenesis and have clinical significance as risk factors for CVD (Kiszel et al., 2007; 
Shanker and Kakkar, 2010).  
 
Interleukin 6 and its signalling effects have been shown to contribute to both atherosclerotic 
plaque formation and its eventual destabilization through several mechanisms (Schuett et al., 
2009). These include endothelial activation, smooth muscle cell proliferation, lymphocyte 
recruitment, and mediation of the acute phase response (Brull et al., 2001). In addition, IL-6 
affects expression of scavenger receptors SR-A and CD-36 which are involved in the uptake 
of modified LDL and therefore promotes foam cell production (Schuett et al., 2009). 
 
The IL-6 -174 SNP location near the ‘hotspot vicinity’ for transcription factor NF-1 binding, 
acts as a repressor of gene expression (Liu et al., 1997). Several population genetic studies 
revealed conflicting results regarding the influence of the IL-6 -174 SNP on IL-6 production 
(Sie et al., 2006). A study of IL-6 levels in a group of healthy men and women (adjusted for 
age, body mass index, gender, and smoking) found low levels, similar to the findings in this 
study, in the presence of the CC genotype: 1.63 (95% CI 1.44–1.86) compared to GG: 2.74 
(95% CI 2.43–3.10) and GC: 2.64 (95% CI 2.35–2.97), (P=0.02 by ANOVA), (Fishman et al., 
1998). Another study conducted on 127 patients (following coronary artery bypass graft 
71 
 
surgery) showed a recessive effect of the C-allele resulting in an increase IL-6 levels (Brull et 
al., 2001).  
 
In this study, the highest levels of IL-6 were detected in non-diabetic CAD subjects with the 
homozygous G allele (p=0.0001, Figure 4.2). The transcriptional regulation of IL-6 is highly 
complex and nearby genetic variants may influence transcription of the IL-6 gene (Shanker 
and Kakkar, 2010). The data from this study indicates the CAD subjects grouped according to 
genotype presented with highest IL-6 levels had corresponding elevated levels of CRP. A 
study in an Italian group of 88 patients assessed the prognostic significance of IL-6 in the 
diagnosis of acute myocardial infarctions. They found that elevated creatine kinase-MB 
(p<0.05) and IL-6 levels (p<0.01) were independently associated with a final diagnosis of 
acute myocardial infarctions. Elevated IL-6 levels also significantly predicted the risk of AMI 
(OR=2.47, p=0.006) (Ferroni et al., 2007). 
 
In 2005 the Physicians Health Study reported that the T-allele was associated with increased 
risk of myocardial infarction, although associated with lower CRP levels (Miller et al., 2005); 
which suggested that this may be due to the complex regulatory mechanisms involved in CRP 
production. These SNPs in the CRP promoter region viz., the rs3093032 and 3872C/T and 
5237A/G affect transcription factor binding, transcriptional activity and CRP levels (Carlson et 
al., 2005; Miller et al., 2005). In this investigation of the tri-allelic CRP -390C/A/T promoter 
polymorphism, we found an increased risk of CAD in the presence of the homozygous wild-
type CC genotype. The Indian control group (who were diabetic and non-diabetic) with the 
homozygous CRP -390 C-allele, though not statistically significant, also presented with the 




Binding of transcription factors regulate CRP gene expression and the -390 T-allele was 
associated with higher promoter activity (Szalai et al., 2005). This finding is in agreement with 
data from participants in the Framingham heart study which showed an association between 
the minor A and T alleles of the CRP -390 C/A/T polymorphism and higher CRP levels 
(Kathiresan et al., 2006). The current data, however, also shows highest levels of CRP in the 
presence of the T-allele in CAD patients, but the frequency of patients presenting with this 
allele is too small to draw any conclusions. In the presence of either the variant A or T alleles 
grouped together (in order to increase statistical power) compared to the homozygous wild-
type C genotype, median levels were higher. 
 
It has been well established that pro-inflammatory markers could serve as biomarkers for risk 
assessment of CAD. A relevant study, described above, concluded that IL-6 may behave as 
an adjunctive diagnostic tool to assist in the risk assessment of acute myocardial infarctions. 
The presence of polymorphic variants in genes of these molecules, however, should be taken 




Single nucleotide polymorphisms in the promoter region of IL-6 and CRP genes may 
contribute to levels of these pro-inflammatory factors which play a role in the pathogenesis of 
atherosclerosis. The present study indicates a potential protective effect of the IL-6 -174 C-






THE EFFECTS OF ATORVASTATIN ON OXIDATIVE STRESS, METABOLIC ACTIVITY 




Heart disease is a global health problem that claims millions of lives annually. The target of 
drug intervention is the underlying cause of vascular disease - atherosclerosis. Statins are 
very important drugs in cardiovascular medicine. Large clinical trials have shown a significant 
reduction in the proportion of cardiovascular deaths in patients on statin therapy (Wright et al., 
1994; Shepherd et al., 1995; Schwartz et al., 2001). It is well known that statins reduce the 
risk of myocardial infarction, stroke, and death, primarily via the competitive inhibition of 
HMGCR, the rate-limiting enzyme of cholesterol synthesis (Strandberg et al., 2004). Other 
factors which play a key role in the development and progression of heart disease are nitric 
oxide and acute-phase CRP (Rao and Milbrandt, 2010). The synthesis of both cholesterol and 
CRP occur in the liver. The first pass metabolism of statins also occurs in the liver, via the 
cytochrome P450 (CYP) group of enzymes.  
 
Atorvastatin (Figure 5.1) is a frequently prescribed HMGCR inhibitor for patients with CAD. 
The differences between HMGCR inhibitors are their pharmacokinetic properties (Igel et al., 
2001; McTaggart et al., 2001). Atorvastatin is a synthetic statin derived from mevalonate and 
contains three main groups which include the HMGC analogue and two hydrophobic hydroxy-
hexahydro naphthalene ring structures (Schachter, 2005). During metabolism of atorvastatin, 
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the acid form is biotransformed to a lipophilic lactone, by coenzyme A-dependent or an acyl 
glucuronide intermediate pathway. Both atorvastatin and its lactone form are further 
metabolized by CYP3A4 and to a lesser extent CYP2C8. The atorvastatin lactone is 
hydrolyzed to an acid form nonenzymatically or by esterases and paraoxonases (Lennernas, 
2003; Neuvonen et al., 2006). 
 
 
Figure 5.1 Chemical structure of atorvastatin (Bracha et al., 2010). 
 
The pharmacological properties of statins include anti-inflammatory effects, vasodilation, and 
antithrombotic activity (Boyle, 2005; Mangat et al., 2007). Amongst these pleiotropic effects, 
statins have also been reported to influence the progression of atherosclerosis (Grothusen et 
al., 2005). The antioxidant effects of statins is achieved by reducing oxLDL (Li et al., 2002), 
ROS and NADPH oxidase activity (Figure 5.2) (Delbosc et al., 2002; Wassmann et al., 2002; 
Yu et al., 2005; Forstermann, 2008; Guasti et al., 2008; Deo et al., 2012) increasing 





Figure 5.2 Inhibition of the mevalonate pathway by statins (Endres, 2005). 
 
A study assessing the hepatotoxicity of statins concluded that “statins are remarkably safe 
from a hepatic standpoint, but there are several issues related to their usage in humans that 
require further research and scrutiny” (Chalasani, 2005). A recent review on the epigenetic 
effects of common pharmaceuticals assessed possible mechanisms of drug-induced 
epigenetic changes (Csoka and Szyf, 2009). Three main epigenetic processes exist in a 
normally regulated genome, i.e., DNA methylation, histone modification and miR interactions. 
 
MicroRNAs control gene expression and modulate multiple target transcripts in eukaryotic 
cells (Leung et al., 2006; Asirvatham et al., 2008). The role of miRs in coordinating immune 
responses is by regulating a repertoire of genes in various immune cells (Chen et al., 2004; 
Cobb et al., 2006; O'Connell et al., 2007; Welker et al., 2007; Asirvatham et al., 2008; 
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Baltimore et al., 2008). A recent study identified 275 predicted immune gene-miRNA 
interactions which included transcription factors, inflammatory cytokines and signalling 
molecules (Asirvatham et al., 2008). This has important implications for CAD as chronic 
inflammation is a critical role-player in atherosclerotic development and progression. 
 
One of the first studies to assess a differential effect of statins on miRNA expression 
examined the physiological role of miR-221 ⁄ 222 on the proliferation of endothelial cells 
obtained from patients with CAD. In the study, atorvastatin increased endothelial progenitor 
cell numbers and decreased miR-221 ⁄ 222 levels in patients with CAD, possibly contributing 
to the beneficial effects of the lipid lowering therapy of statins (Minami et al., 2009).  
 
As mentioned in chapter 1, the primary function of statins is to inhibit cholesterol biogenesis in 
the liver but other metabolic products such as creatine also enter peripheral circulation. This is 
evidenced by the fact that statin therapy is associated with myopathy (Phillips et al., 2002). It 
has been established that miRNAs play a crucial role in coordinating the inflammatory 
response by directly affecting the transcriptome and thus heavily influence gene expression 
patterns (Asirvatham et al., 2008). There is emerging evidence for modulation of the 
transcriptome by statins (Wang et al., 2011). Limited data is available on the effects of these 
drugs on miRNAs involved in the regulation of specific biological pathways. 
 
The miRFinder miR PCR Array provides an ideal platform to assess at least 84 of the most 
abundantly expressed and best characterised miRNAs in the miRNA database. These 
miRNAs can regulate one or more mRNA transcripts, and although well-characterised, the 
complex role of each miRNA is not completely understood. The liver plays an integral role in 
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the metabolism of statins and the effects thereof. In this arm of the study the effect of 
atorvastatin on the metabolism (ATP, LDH), oxidative damage (ROS, RNS) and miRNA 
profile in a liver cell line, HepG2 cells, was assessed. A pathway finder based miRNA PCR 
array panel was used to profile 84 miRNAs and identify possible targets from which a 




5.2 Materials & Methods 
 
HepG2 cells were purchased from Highveld Biologicals (Johannesburg, SA). Cell culture 
reagents were purchased from Whitehead Scientific (Johannesburg, SA). ECL-LumiGlo 
chemiluminescent substrate kit was purchased from Gaithersburg (USA) and western blot 
reagents were purchased from Biorad (SA). All other reagents and consumables were 
purchased from Merck (SA), unless otherwise stated. 
 
 
5.2.1 Maintenance of HepG2 cells in culture  
 
The liver is the most important drug metabolising organ in mammals. Liver cell lines are 
generally used for the assessment of metabolism or bioactivation of xenobiotics. The 
commonly used human HepG2 cells have an epithelial like morphology which resembles liver 




The best environment for growing cells in vitro should be matched as close as possible to the 
natural physiological conditions. The essential requirements are an optimum environment of 
temperature, pH, gas phases, growth substrate and media containing necessary nutrients. 
The optimal temperature is provided by the use of a humidified incubator supplied with 5% 
carbon dioxide (CO2). The gas phases supplied to the culture includes oxygen which is 
maintained at atmospheric pressure, and CO2 to ensure that the bicarbonate and CO2 tension 
is in equilibrium. 
 
HepG2 cells were cultured (37
oC, 5% CO2) to 90% confluency in 25cm
3 flasks in complete 
culture media (CCM) [Eagle’s minimum essential medium, 10% foetal calf serum, 1% L-
Glutamine and 1% penstrepfungizone]. The culture medium is by far the most important 
single factor in culturing cells. The extracellular medium must meet the essential requirements 





In order to sub-culture and plate cells for the various experimental assays, the process of 
trypsinisation was used to detach cells once 90% confluency was reached. The process of 
trypsinisation involved the critical step of rinsing the cells with 3ml aliquots of warm 0.1M PBS 
and incubating the cells with 1ml of trypsin-EDTA (Lonza) for 1min.  
 
The cells were monitored using an inverted light microscope (Olympus IXSI; 20x 
magnification) and once rounded the trypsin was discarded and CCM was added to the flask 
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of cells. The flask was agitated to detached cells and the cell suspension was then 
enumerated by dye exclusion using a haemocytometer. Trypan blue (0.4%) was utilised in a 
dye exclusion procedure for cell counting.  
 
The principle of dye exclusion using trypan blue is based on compromised cell membranes in 
dead/damaged cells which readily allow entry of the dye into the cells and are stained blue 
whereas viable cells remain unstained. 
 
 
5.2.2 Cell proliferation and metabolic activity assay 
 
The effect of atorvastatin in HepG2 cells was measured using a methyl tetrazolium dye 
reduction assay, the [3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT) 
assay. This assay measures cell proliferation/metabolic activity in vitro. This technique is 
particularly useful for cells that are metabolically active based on their redox potential and 
capacity of dehydrogenase enzymes to convert yellow water-soluble salt into a purple water-
insoluble formazan product. The insoluble crystals are then dissolved in dimethyl sulfoxide 
(DMSO) and the absorbance is read on a spectrophotometer. The amount of formazan 
produced is directly proportional to cell number thus allowing for the determination of cell 
viability and proliferation (Supino, 1995).  
 
HepG2 cells (15,000/well) were incubated for 24h with a range of concentrations of 
atorvastatin (Sigma Aldrich, SA) (1µM, 10µM and 20µM) in triplicate in a microtitre plate 
together with an untreated control (cells incubated with CCM only). The concentration and 
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time used for this experiment was based on the half-life of atorvastatin (20h-30h) and the 
recommended physiological dose between 10mg and 40mg/day, the bioavailability of which is 
14%. Each experiment was conducted twice on separate occasions in order to confirm the 
data results from the first set matched the repeated experiment. The cells were then 
incubated (37oC, 5%CO2) with the MTT substrate (5 mg/ml in PBS) for 4h.  Thereafter all 
supernatants were aspirated, and DMSO (100 µl/well) was added to the wells.  Finally the 
optical density was measured at 570 nm and a reference wavelength of 690 nm with an 
ELISA plate reader (Bio-Tek µQuant).  
 
The net MTT-dependant absorbance of each sample was calculated by subtracting the 
average absorbance of the blank from the average absorbance of each sample. Data are 
represented as % cell viability plus or minus the standard deviations.  Percentage cell viability 
was calculated by utilising the following equation:  
 
% Cell viability =    mean absorbance of treated cells x 100  
                                      mean absorbance of control cells  
 
 
5.2.3 HepG2 cell culture treatment for subsequent assays 
 
HepG2 cells were seeded (200,000cells/flask) in 25cm3 flasks and grown to approximately 
90% confluency. For each assay, three 25cm3 flasks of untreated cells and three 25cm3 flasks 
of 20µM atorvastatin treated cells were incubated for 24h (37oC, 5% CO2). Following 
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incubation, the supernatant was aspirated and stored at -80oC; and cells were rinsed thrice 
with 2ml of 0.1M PBS to remove any residual media.  
 
 
5.2.4 The ATP quantification assay 
 
The level of intracellular ATP was measured using a CellTiter-Glo® kit (Promega, United 
States, Madison, WI, USA).  The ATP quantification assay utilises bioluminescence to 
ascertain ATP levels in cells. The assay is based on the conversion of a luciferase-inactive 
derivative by ATP in the presence of magnesium ions to D-luciferin (Figure 5.3).  
 
 
Figure 5.3 The luciferase reaction where mono-oxygenation of luciferase occurs in the 
presence of magnesium, ATP and molecular oxygen. 
 
D-luciferin, a luciferase substrate, reacts with the enzyme luciferase to produce oxyluciferin 
and release energy in the form of luminescence. This luminescent signal is directly 
proportional to the concentration of ATP present in the cells. 
 
For the procedure, treated cells were seeded into a white luminometer plate (20,000 
cells/well) in triplicate followed by the addition of 10l/well of the reagent. The plate was 
agitated and incubated in the dark (30min; RT) to allow for cell lysis and the luciferace-based 
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reaction to occur (Figure 5.3). Thereafter, the luminescent signal was measured on a 
microplate luminometer (Turner Biosystems, USA). The ATP concentration was expressed as 
Relative Light Units (RLU). 
 
 
5.2.5 The lactate-dehydrogenase (LDH) assay 
  
The LDH cytotoxicity detection kit (Roche) was used to measure cell death/damage of 
atorvastatin treated HepG2 cells. Lactate dehydrogenase is a stable cytosolic enzyme which 
is released from cells due to compromised cell membrane integrity. A colorimetric assay was 
used for the quantification of LDH activity in the supernatant of atorvastatin treated HepG2 
samples. The assay is a two-step enzymatic reaction where NAD+ is reduced to NADH/H+ by 
the conversion of lactate to pyruvate. Thereafter, a diaphorase catalyst transfers H/H+ from 
NADH/H+ to a tetrazolium salt to yield a formazan product. To measure LDH activity, 
supernatant (100µl) was transferred into microtitre plates in triplicate. Thereafter, substrate 
mixture (100µl) containing catalyst (diaphorase/NAD+) and dye solution (INT/sodium lactate) 
from the kit was added to the supernatant and allowed to react at ambient temperature for 25 
minutes. Optical density of the resulting formazan product was measured at 500nm with an 
ELISA plate reader (Bio-Tek uQuant). Results are represented as mean optical density. 
 
5.2.6 The thiobarbituric acid reactive substance assay 
 
One of the most commonly applied assays is the thiobarbituric acid (TBA) reactive substance 
(TBARS) assay, which measures malondialdehyde (MDA) formed in peroxidising lipid 
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systems (Halliwell and Chirico, 1993). This method is based on the condensation of two 
molecules of TBA with one molecule of MDA to form a pink chromagen (TBA pigment; Figure 
5.4), the intensity of which is a measure of MDA concentration (lipid peroxidation) and can be 
measured by spectrophotometry at 532nm.  
 
 
Figure 5.4 Reaction between thiobarbituric acid (TBA) and malondialdehyde (MDA) to 
form the thiobarbituric acid pigment (Bastos et al., 2012). 
 
Approximately 500µl of supernatant per treatment was transferred to appropriately labelled 
glass test tubes containing 400µl 2% phosphoric acid (H3PO4). A blank sample (negative 
control) containing homogenate from the control was also included in order to correct 
background absorbance. A 200µl aliquot of 7% H3PO4 was then dispensed into each test tube 
followed by the addition of 400µL TBA/Butylated hydroxytoluene (BHT: Merck, SA) solution 
(BHT is added to the TBA solution to prevent oxidation in the reaction during heating) to each 
sample, and 400µL of 3mM HCl to the blank.  
 
All test tubes were briefly vortexed and the pH of each solution was subsequently adjusted to 
1.5 using 1M HCl. The test tubes were thereafter placed in a water bath (100ºC). After 15min, 
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the tubes were removed and allowed to cool to room temperature before pipetting 1.5ml of 
butanol into each tube.  
 
All test tubes were then vortexed (1 min each) and the samples were allowed to separate. 
Approximately 500µl of the butanol (which comprised the upper phase of the solution present 
in the test tube) was then transferred to sterile 1.5ml tubes and centrifuged (2 500xg, 6min, 
24ºC).  
 
A 100µl aliquot of each sample was then pipetted in triplicate to wells of a 96-well microtiter 
plate. The absorbance of the butanol phase was measured at 532nm with a reference 
wavelength of 600nm using a Bio-Tek µQuant microplate spectrophotometer. 
 
 
5.2.7 The Griess assay 
 
Nitric oxide production was measured by the standard Griess assay described by (Miranda et 
al., 2001). This assay relies on a diazotization reaction that detects NO2- in solution as shown 





Figure 5.5 Principle reaction of the Griess assay.  
 
The concentration of nitrites in supernatant was determined as described by Miranda et al. 
(2001). A positive control of 100µM nitrate solution was prepared in 0.1M PBS, and a blank 
was prepared (0.1M PBS only). Each sample was aliquoted into wells of a 96-well microtitre 
plate (100µl, in triplicate). Vanadium (III) chloride (8mg/ml, 100µl) was then added to each 
well followed by 50µl of sulfanilamide (2%) and 50µl of N-(1-Naphthyl) ethylenediamine 
dihydrochloride (0.1% in 5% HCl).  
 
The plate was then incubated (37oC, in the dark, 45min). The absorbance was measured on a 
Biotek® µquant spectrophotometer (540nm, reference 690nm). The net absorbance was 
calculated by subtracting the absorbance of the blank from the treated samples. The data is 






5.2.8 Isolation of RNA from atorvastatin treated HepG2 cells 
 
The TRI Reagent® solution was used for the isolation of total RNA. The TRI Reagent solution 
combines phenol and guanidine thiocyanate in a monophasic solution to rapidly inhibit RNase 
activity. The serum samples were homogenized in TRI Reagent solution, and the homogenate 
was then separated into an aqueous and organic phase by adding bromochloropropane and 
centrifuging. Total RNA (containing ribosomal RNA, mRNA and transfer RNA) then partitions 
into the aqueous phase. The RNA was precipitated with isopropanol, and finally washed with 
ethanol and solubilised. 
 
An aliquot of 500µl Tri Reagent® Solution (Ambion) was added to 500µl of for treated and 
untreated HepG2 cells isolation of total RNA and incubated (5min, RT). The lysed cells were 
transferred to 500µl of 0.1M PBS in sterile 1.5ml tubes. An aliquot of chloroform (100µl) was 
then added to each sample and vortexed vigorously for 15 sec and incubated for 3min at RT 
before centrifugation (12,000xg, 4oC). The resulting aqueous phase was carefully transferred 
to a fresh tube to which 250µl of isopropanol was added to each sample and incubated for 1h 
at -80oC. Following incubation, samples were thawed at RT and then centrifuged (20min, 
12,000xg, 4oC). The supernatant was removed and the pellet was washed with 75% cold 
ethanol (500µl) and centrifuged (15min, 7,400xg, 4oC). The ethanol was removed and the 
pellet was allowed to air dry before being resuspended in 15µl nuclease free water and 






5.2.9 cDNA synthesis 
For each sample, cDNA was synthesised using the First-Strand Kit (Qiagen, United States). 
Approximately 100ng of RNA  was added to a sterile PCR tube with 1µl miR reverse 
transcription primer & ERC Mix (M1), 2µl 5X miR reverse transcription Buffer 2  (M5), 1µl miR 
RT enzyme Mix (M3), 1µl nucleotide mix (M4) and 10µl RNase-free H2O per sample. The 
contents were mixed gently and incubated at 37oC for 2h. Samples were then heated at 95oC 
for 5min to degrade RNA & inactivate reverse transcriptase and then placed on ice for at least 
1min before 90µl of RNase-free H2O was added to each 10µl cDNA synthesis reaction.  
 
 
5.2.10 MicroRNA SuperArray Analysis by quantitative PCR, analysis and selection of 
significant microRNAs 
 
The Human miFinder miRNA PCR Array (MIHS-001Z, Qiagen, United States) was used to 
profile the expression of 84 miR species (Table 5.1). Each sample was prepared for analysis 
by adding 1275µl 2x RT2 SYBR Green PCR Mastermix to 100µl of the diluted cDNA reaction 
product described in section 5.2.4, and 1175µl nuclease free water. The PCR array plates 
were then carefully removed from sealed bags and the experimental cocktail was loaded into 
each well (25µl). The plates were sealed with optically thin wall cap strips and inspected from 
the bottom to ensure that no bubbles were formed. Plates were centrifuged at 250xg for 2min 
at RT to remove bubbles and then transferred to Real-time Chromo4 thermocycler (Biorad, 
SA) pre-set with appropriate thermocycling conditions. The miScript Primer Assays (Qiagen, 




Data was normalized using U6 small RNA expression. Differences in miR expression were 
determined by fold change analysis using the 2–ΔΔCt method (Appendix 3). To stringently 
select miRs which were significantly up- or down-regulated in experimental groups, a 
significance analysis of microarray (SAM) strategy was used. Significant (p<0.05) deviations 
of residuals from normal distribution was used to identify miRs of interest. Data was analysed 
with Microsoft excel (2011) Statplus plug-in and R. 
 
MicroRNA target analysis was conducted using the Targetscan algorithm.  
 
 
5.2.11 Transfection of HepG2 cells with miR-124a-3p mimics and inhibitors 
 
In order to directly assess the effect of miR-124a-3p on mRNA and protein expression, the 
mimic as well as the inhibitor to this miR was purchased (Qiagen, United States). Transient 
transfection of adherent cells involves the introduction of nucleic acids into a cell that does not 
become permanently integrated into the cellular genome, and the effect only lasts a period of 
time. Attractene Reagent is a non-liposomal lipid which enables highly efficient nucleic acid 
transfection with minimal cytotoxicity.  
 
To determine the effect of elevated miR-124a-3p on the mRNA expression of 
guanidinoacetate methyltransferase (GAMT), spermine oxidase (SMO) and arginine-glycine 
amidinotransferase (AGAT) and protein expression of GAMT, HMGCR and p53; cells were 
transfected with the relevant mimic (Syn-hsa-miR-124a-3, MYS0000422, Qiagen, United 
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States) and inhibitor (Anti-hsa-miR-124a-3p, MYS0000422, Qiagen, United States) of miR-
124a-3p.  
 
For the transfection procedure, HepG2 cells were seeded at a density of 400,000 cells/well in 
a 6-well plate and allowed to adhere for 24h (37oC, 5% CO2) and monitored until 80% 
confluency was reached. Lyophilised miR mimics (5nmol) and inhibitors (5nmol) were 
reconstituted with 250µl nuclease free water to obtain a stock concentration of 20uM. On the 
day of transfection, 10µl miR mimic/inhibitor was added to with medium without serum, 
proteins, or antibiotics to a total volume of 60μl to which 2μl of Attractene Transfection 
Reagent was added and mixed by reverse-pipetting. Samples were then incubated for 15min 
(RT) to allow complex formation. During this time CCM was gently aspirated from the cells 
and 1940μl fresh CCM was added such that the final concentration of mimic/inhibitor per well 
was 50nM. The transfection complexes were added in a drop-wise fashion into the 
appropriate well with gentle swirling of the plate to ensure uniform distribution of the 
transfection complexes. An untreated control and a 20µM atorvastatin treatment well were 
included before the cells were incubated under normal growth conditions for 24h and utilized 
for protein extraction. 
 
5.2.12 Gene Expression Analyses of specific targets of highly expressed microRNAs 
 
The targets of the most up-regulated miRs were assessed using TargetScan. A few targets of 
interest involved in the synthesis of creatine and polyamines were identified and assessed by 




Total RNA was extracted as described in section 5.2.8. RNA was reverse transcribed using 
the iScript cDNA synthesis kit (Biorad, SA). Real-time PCR was performed using the iQ 
Superscript reagent (Biorad, SA). Levels of mRNA for SMO, AGAT and GAMT were 
quantified with standardization of levels to the average of a housekeeping gene: GAPDH.  
The primers utilized were as follows:  
    GAMT:  sense         5’-TGGCACACTCACCAGTTCA-3’ 
                 antisense   5’-AAGGCATAGTAGCGGCAGTC-3’ 
    AGAT:  sense         5’-TCACGCTTCTTTGAGTACCG-3’ 
                           antisense   5’-TCAGTCGTCACGAACTTTCC-3’  
    SMO:  sense         3’-GGATGAGGATGAGCAGTGGTC-5’,  
                          antisense   3’-CGACACGGTCACAATCACATG -5’ 
               GAPDH:    sense         3’-CAACAGCCTCAAGATCATCAGC-5’,  
                          antisense   3’-TGAGTCCTTCCACGATACCAAAG-5’ 
 
The PCR conditions were as follows: 40 cycles of a denaturation step (95oC, for 30sec), an 
annealing step (56oC, for 15s), a plate read and an elongation step at 72oC. This was followed 
by a melt curve from 60oC to 95oC, with a plate read every 2oC held for 30s. For GAMT, 
AGAT SMO and GAPDH, the final concentrations of primers used were 300nM and 100nM, 
respectively. The method described by Livak and Schmittgen (2001) was used to calculate a 
relative fold change of each gene from cycle threshold values (Livak and Schmittgen, 2001). 








5.2.13 Protein Extraction, Quantification and Standardisation 
 
HepG2 cells were treated for protein isolation as described in section 6.2.8. Approximately 
200µl of the CytoBuster™ protein extraction reagent (a formulation of detergents optimised for 
efficient extraction of soluble proteins from mammalian cells) was added to a 25cm3 flask of 
treated HepG2 cells; placed on ice for 10 min before the cells were harvested using a cell 
scraper. The cell solution was then centrifuged (600xg, 10 min, 24ºC) and the resulting 
supernatants (450µl) served as the crude protein extract. The supernatants were transferred 
to appropriately labelled 1.5ml microcentrifuge tubes and kept on ice until utilised. 
 
Crude protein extracts were quantified using the bicinchoninic acid (BCA) assay. The BCA 
assay is a colorimetric assay which relies on two reactions. First, the peptide bonds in protein 
reduce Cu2+ ions to Cu1+. The amount of Cu2+ reduced is proportional to the amount of protein 
present in the solution and second, two molecules of BCA chelates with each Cu1+ ion, 
forming a purple-coloured product that strongly absorbs light at a wavelength of 562nm.  
 
A standard curve of serially diluted bovine serum albumin (BSA: 0, 0.2, 0.4, 0.6, 0.8 and 
1.0mg/ml) was used to construct a standard curve (Appendix 4). An aliquot of 25µl of each 
sample and the relevant standards (BSA) were added to appropriately labelled wells.  
 
The BCA working solution (202µl, 4µl Cu2SO4 and 198µl BCA) was then transferred into each 
well and incubated (37ºC, 30 min) and the absorbance was measured at 562nm using a 
spectrophotometer (BioTek µQuant). All samples were then diluted using storage buffer [0.1M 
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KH2PO4 (pH 7.4), 0.5mM K2EDTA, 0.1mM DTT and 0.25M sucrose] and standardised to 
1mg/ml (Appendix 4). 
 
5.2.14 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis  
 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is based on the 
separation of proteins according to size. Sample preparation prior to being resolved by SDS-
PAGE is accomplished by denaturation with sample buffer containing β-mercaptoethanol and 
SDS. The β-mercaptoethanol reduces disulphide bridges holding together the protein tertiary 
structure, whereas SDS, an anionic detergent, binds strongly to and denatures the protein. 
This results in the proteins becoming linear and with a uniform charge (Wilson and Walker, 
2005). 
 
Once loaded, the negatively charged protein-SDS complexes move toward the anode and as 
they pass through the resolving gel, the proteins separate due to the molecular sieving 
properties of the gel (Wilson and Walker, 2005).  
 
The Mini-PROTEAN 3 SDS-PAGE apparatus (Biorad, SA) was assembled according to 
manufacturer’s instructions. A 7.5% resolving gel [dH2O, 1.5M Tris-HCl (pH 8.8), 10% (w/v) 
SDS, 30% Acrylamide/bis, 10% APS, TEMED] was prepared and added in-between the 
cleaned glass plates. A 4% stacking gel [dH2O, 0.5M Tris-HCl (pH 6.8), 10% (w/v) SDS, 30% 
Acrylamide/bis, 10% APS, TEMED] was then added in-between the glass plates. A 1.5mm 
plastic 10-well comb was placed into the stacking gel between the glass plates. Following 
polymerization, samples prepared in Laemmli buffer [dH2O, 0.5M Tris-HCl (pH 6.8), glycerol, 
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10% SDS, β-mercaptoethanol, 1% bromophenol blue, (1:1)] were loaded into appropriate 
wells. A molecular weight marker (Mwt) was loaded into a separate well in order to identify the 
weight of the migrated proteins. A 1x electrode buffer (dH2O, Tris, glycine, SDS; pH 8.3) was 
then added to the tank and samples were electrophoresced (150V, 1h, on ice). After 
electrophoresis, gels were allowed to equilibrate in transfer buffer (25mM Tris, 192mM 
glycine, 20% v/v methanol; pH 8.3) (10min, RT).  
 
5.2.15 Western blotting 
 
Western blotting is a technique that allows for the electrophoretic protein transfer from a SDS-
PAGE gel to a nitrocellulose membrane, which can then be probed with antibodies. Primary 
polyclonal or monoclonal antibodies react specifically with antigenic epitopes presented by 
target proteins attached to the membrane. A secondary antibody, specific to the primary 
antibody conjugated with horseradish peroxidase (HRP) allows for the detection of the bound 
antibody. The HRP-conjugated secondary antibodies are then able to catalyse a reaction 
between hydrogen peroxide and a chemiluminescent substrate, luminol. This is a light-
emitting reaction which is detected a chemiluminescence detection imaging system and 
captured as an image which can be quantified.  
 
For the procedure, a set of fibre pads and nitrocellulose were pre-soaked in transfer buffer. A 
gel sandwich was assembled by first placing a fibre pad on the area of the gel holder cassette 
located closest to the cathode, followed by filter paper, the equilibrated gel, the nitrocellulose 
membrane, a second filter paper and a final fibre pad. The gel holder cassette was then tightly 
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closed and placed into the transfer module and mini tank with transfer buffer. Proteins were 
then transferred to the nitrocellulose membranes at a constant current of 400mA for 1 h.   
 
After the transfer, the nitrocellulose membranes were blocked (1h, RT) with 5% BSA in TTBS 
[100ml; Tris-buffered saline (TBS) containing 0.5% Tween20] after which, each membrane 
was incubated for 1h with primary antibody (anti-mouse GAMT. ab119269 (Abcam); anti-
rabbit phosphoP53 (ser15) 9284S (Cell Signalling)) diluted 1:1 000 in 1% BSA in TTBS. After 
incubation, the primary antibody was discarded and the membranes were washed thrice 
(10min, 10ml TTBS). The membranes were subsequently incubated with HRP-conjugated 
goat anti-mouse IgG secondary antibody (ab7023, diluted 1:2 000 in 1% BSA in TTBS, RT) 
and anti-rabbit IgG secondary antibody (ab9746, diluted 1:2 000 in 1% BSA in TTBS, RT) for 
1h. The secondary antibody was then discarded and the membrane was washed thrice 
(10min) with 10ml TTBS.  
 
Development of each membrane was facilitated by chemiluminescence detection. Briefly, the 
two chemiluminscence reagents (luminol/enhancer and peroxide buffer) comprising the KPL 
Lumiglo HRP substrate kit were mixed in a 1:1 ratio. Approximately 1ml of this mixture was 
dispensed onto the nitrocellulose membrane already placed into the chamber of an Alliance 
2.7 Gel Documentation System (UViTech). The images of the protein bands on the 
membrane became visible following exposure. The captured image was assessed using the 






5.2.16 Statistical analysis 
Statistical analysis for differences between groups was calculated using the Graphpad Prism 
Software. The Mann Whitney test was used for differences between two groups and the 
Kruskal-Wallis Multiple comparisons test was used to test for differences between more than 
two groups.  
 
5.3 Results 
5.3.1 Cell proliferation, metabolic activity and cytotoxicity of atorvastatin treated HepG2 
cells  
 
The MTT assay was used as a measure of cell proliferation/metabolic activity of atorvastatin 
in HepG2 cells. Following a 24h incubation with atorvastatin at the low concentrations of 1µM 
(104±0.5%) and 10µM (102±8%), no toxicity was observed (Figure 5.6). 
 
Figure 5.6 Cell viability of HepG2 cells treated with atorvastatin for 24 hours. Data is 




The lowest measure of proliferation/metabolism was observed at 20µM, with 82±9.8% (Figure 
5.6). No statistical differences between treatments were found. According to an in vitro study, 
60µM atorvastatin was used to assess its effect on primary human-derived hepatocytes 
(Schroder et al., 2011). For all subsequent tests in our study, HepG2 cells were treated with 
20µM atorvastatin for 24h. 
 
Statin treatment increased the release of LDH (an intracellular enzyme), as measured in cell 
culture fluid after 24h. A simultaneous assessment of intracellular energy levels indicated a 
reduction in ATP levels (Figure 5.7). 
  
 
Figure 5.7 Levels of (A) ATP and (B) LDH activity in atorvastatin treated HepG2 cells. 
RLU: relative light units, OD: optical density. **p=0.001, Mann Whitney test, Mann 
Whitney U: 0.00 and Sum of ranks: 26, 63. 
 
Basal levels of ATP in the control sample measured 5.28x106±0.82x106 RLU and decreased 
to 4.13x106±0.34x106 RLU in the presence of atorvastatin (Figure 5.7A); this finding however, 
was not statistically different. The decrease in ATP levels is in keeping with the decrease in 
cell proliferation/metabolic activity as measured by the MTT assay (Figure 5.6). Statin treated 
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cells had increased LDH levels (1.11±0.03 units) as compared to untreated cells (0.95±0.02 
units) (p=0.001). 
 
In order to evaluate the effect of atorvastatin on oxidative stress and NO synthesis, lipid 
peroxidation and nitrites levels were measured. 
 
 
Figure 5.8 Levels of (A) MDA and (B) Nitrites from atorvastatin treated HepG2 cells. OD: 
optical density. **p=0.0092 (A), Mann Whitney test, Mann Whitney U: 8.00 and Sum of 
ranks: 142, 29; *p=0.044 (B), Mann Whitney test, Mann Whitney U: 4.00 and Sum of 
ranks: 25, 41. 
 
The MDA levels in atorvastatin treated HepG2 cells was reduced from 0.133±0.003 units in 
control cells to 0.126±0.005 units (p=0.009).  Also, atorvastatin increased the nitrite levels as 
compared to the controls (0.0312±0.003 units vs. control: 0.027±0.001 units, p=0.044). A 






5.3.2 MicroRNA expression profile in statin treated HepG2 cells 
No study, to date, assessed the role of miRNAs in HepG2 cells treated with atorvastatin. The 
miRNA pathway finder was used to profile the atorvastatin induced differential regulation of 
miRNAs in HepG2 cells (Figure 5.9, appendix 5). 
 
 
Figure 5.9 The differential expression of miR in atorvastatin treated HepG2 cells 
(represented as a heatmap). 
 
MicroRNAs most significantly upregulated by atorvastatin included miR-302a-3p (3.05-fold), 
miR-302c-3p (3.61-fold), miR-124-3p (3.90-fold) and miR-222-3p (4.4-fold) (Figure 5.10); miR-
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19a-3p, miR-101-3p and let-7g were downregulated (3.63-fold, 2.92-fold, 2.81-fold, 
respectively) (Figure 5.10).  
 
The TargetScan tool was used to assess the mRNA targets of differentially regulated miRs. A 
list of the top 1000 gene targets was compiled for the 4 most up-regulated miRs (miR-222, 
miR-302a, miR-302c and miR-124a).  
 
 
Figure 5.10 Fold change of miRs in HepG2 cells treated with 20µM atorvastatin for 24 
hours. Data represented as a fold change relative to the untreated control. 
 
Following a thorough screening of the potential targets, a list of targets was compiled. These 
were separated according to their role in specific biological processes such as metabolism 






Table 5.1 Target genes of amiR-124a, bmiR-222 and cmiR-302a/c associated with 
carbohydrate and lipid metabolism and transport. 









 ACAA2 NM_006111 acetyl-CoA acyltransferase 2  
 
c
 ACADSB NM_001609 acyl-CoA dehydrogenase, short/branched chain  
 
a,c
 ACADVL NM_000018 acyl-CoA dehydrogenase, very long chain  
 
c
 ACOX1 NM_001185039 acyl-CoA oxidase 1, palmitoyl  
 
a
 ACSL1 NM_001995 acyl-CoA synthetase long-chain family member 1  
 
c
 AGPAT3 NM_001037553 1-acylglycerol-3-phosphate O-acyltransferase 3  
 
a
 AGXT2L1 NM_001146590 alanine-glyoxylate aminotransferase 2-like 1  
 
a
 ALDH1L2 NM_001034173 aldehyde dehydrogenase 1 family, member L2  
 
c
 ALDH3A2 NM_000382 aldehyde dehydrogenase 3 family, member A2  
 
c
 ALDH3B1 NM_000694 aldehyde dehydrogenase 3 family, member B1  
 
c
 ALDH7A1 NM_001182 aldehyde dehydrogenase 7 family, member A1  
 
a
 ATAD2B NM_001242338 ATPase family, AAA domain containing 2B  
 
a
 ATPAF1 NM_001042546 
ATP synthase mitochondrial F1 complex assembly 
factor 1  
 
c
 B3GALT5 NM_006057 
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 5  
 
c
 B4GALT6 NM_004775 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 6  
 
a,c
 C1GALT1 NM_020156 
core 1 synthase, glycoprotein-N-
acetylgalactosamine 3-beta-galactosyltransferase, 1  
 
b
 CAMKK1 NM_032294 
calcium/calmodulin-dependent protein kinase kinase 
1, alpha  
 
c
 CAMTA1 NM_015215 calmodulin binding transcription activator 1  
 
c
 CERK NM_022766 ceramide kinase  
 
a
 CERS2 NM_022075 ceramide synthase 2  
 
c
 COA5 NM_001008215 cytochrome C oxidase assembly factor 5  
 
c
 COX15 NM_004376 
COX15 homolog, cytochrome c oxidase assembly 
protein (yeast)  
 
c
 COX19 NM_001031617 
COX19 cytochrome c oxidase assembly homolog 
(S. cerevisiae)  
 
a
 CPT1A NM_001876 carnitine palmitoyltransferase 1A (liver)  
 
a
 CRAT NM_000755 carnitine O-acetyltransferase  
 
a
 CRTC3 NM_001042574 CREB regulated transcription coactivator 3  
 
a,c
 CYCS NM_018947 cytochrome c, somatic  
 
c





 DGAT2 NM_032564 diacylglycerol O-acyltransferase 2  
 
c
 DGKB NM_004080 diacylglycerol kinase, beta 90kDa  
 
b




 DGKQ NM_001347 diacylglycerol kinase, theta 110kDa  
 
a
 DHCR24 NM_014762 24-dehydrocholesterol reductase  
 
c
 DHFRL1 NM_001195643 dihydrofolate reductase-like 1  
 
a
 DHRS1 NM_001136050 dehydrogenase/reductase (SDR family) member 1  
 
c
 EHHADH NM_001166415 




 ELOVL5 NM_001242828 ELOVL fatty acid elongase 5  
 
a




 FOXRED2 NM_001102371 








 FUT4 NM_002033 








 GALNTL1 NM_001168368 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase-like 1  
 
a
 GCDH NM_000159 glutaryl-CoA dehydrogenase  
 
c
 GFPT1 NM_002056 glutamine--fructose-6-phosphate transaminase 1  
 
a
 GFPT2 NM_005110 glutamine-fructose-6-phosphate transaminase 2  
 
a,c
 GGPS1 NM_001037277 geranylgeranyl diphosphate synthase 1  
 
c
 GK NM_000167 glycerol kinase  
 
a
 GK5 NM_001039547 glycerol kinase 5 (putative)  
 
c
 GLO1 NM_006708 glyoxalase I  
 
c
 GNPNAT1 NM_198066 glucosamine-phosphate N-acetyltransferase 1  
 
a
 GPAM NM_020918 glycerol-3-phosphate acyltransferase, mitochondrial  
 
c
 GPD1L NM_015141 glycerol-3-phosphate dehydrogenase 1-like  
 
a
 GPD2 NM_000408 




 GPLD1 NM_001503 




 GPT2 NM_001142466 
glutamic pyruvate transaminase (alanine 
aminotransferase) 2  
 
a





 GXYLT1 NM_001099650 glucoside xylosyltransferase 1  
 
c
 H6PD NM_004285 




 HADH NM_001184705 hydroxyacyl-CoA dehydrogenase  
 
a
 HADHA NM_000182 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), 
alpha subunit  
 
c
 HSD17B7 NM_016371 hydroxysteroid (17-beta) dehydrogenase 7  
 
c
 IDI1 NM_004508 isopentenyl-diphosphate delta isomerase 1  
 
a
 IMPAD1 NM_017813 inositol monophosphatase domain containing 1  
 
a
 INPP5B NM_005540 inositol polyphosphate-5-phosphatase, 75kDa  
 
c
 INPP5F NM_014937 inositol polyphosphate-5-phosphatase F  
 
c
 IVD NM_001159508 isovaleryl-CoA dehydrogenase  
 
c
 KDSR NM_002035 3-ketodihydrosphingosine reductase  
 
a
 L2HGDH NM_024884 L-2-hydroxyglutarate dehydrogenase  
 
c
 LDHD NM_153486 lactate dehydrogenase D  
 
c
 LDLR NM_000527 low density lipoprotein receptor  
 
a
 LDLRAP1 NM_015627 low density lipoprotein receptor adaptor protein 1  
 
a
 LIPE NM_005357 lipase, hormone-sensitive  
 
b
 LPPR1 NM_017753 lipid phosphate phosphatase-related protein type 1  
 
c
 LRP2 NM_004525 low density lipoprotein receptor-related protein 2  
 
a,c







low density lipoprotein receptor-related protein 









 MVK NM_000431 mevalonate kinase  
 
c
 NDUFA10 NM_004544 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa  
 
c
 NDUFC2 NM_001204054 
NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 2, 14.5kDa  
 
a
 OSBP NM_002556 oxysterol binding protein  
 
a
 OSBP2 NM_030758 oxysterol binding protein 2  
 
a
 OSBPL10 NM_001174060 oxysterol binding protein-like 10  
 
a,b
 OSBPL3 NM_015550 oxysterol binding protein-like 3  
 
c
 OSBPL6 NM_001201480 oxysterol binding protein-like 6  
 
a,b
 OSBPL7 NM_145798 oxysterol binding protein-like 7  
 
a





 PAK1 NM_001128620 p21 protein (Cdc42/Rac)-activated kinase 1  
 
c




 PAK7 NM_020341 p21 protein (Cdc42/Rac)-activated kinase 7  
 
c
 PDP2 NM_020786 
pyruvate dehyrogenase phosphatase catalytic 
subunit 2  
 
a
 PEX19 NM_001193644 peroxisomal biogenesis factor 19  
 
c
 PFKFB2 NM_006212 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2  
 
c
 PFKFB3 NM_001145443 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3  
 
c
 PIK3AP1 NM_152309 phosphoinositide-3-kinase adaptor protein 1  
 
a
 PIP4K2C NM_001146259 




 PLCB1 NM_015192 phospholipase C, beta 1 (phosphoinositide-specific)  
 
c
 PLCXD3 NM_001005473 
phosphatidylinositol-specific phospholipase C, X 
domain containing 3  
 
c
 PNPO NM_018129 pyridoxamine 5'-phosphate oxidase  
 
a,c
 PPARA NM_001001928 peroxisome proliferator-activated receptor alpha  
 
a,c
 PPARGC1B NM_001172698 
peroxisome proliferator-activated receptor gamma, 
coactivator 1 beta  
 
a,c
 PXMP4 NM_007238 peroxisomal membrane protein 4, 24kDa  
 
c
 S1PR3 NM_005226 sphingosine-1-phosphate receptor 3  
 
c
 SC5DL NM_001024956 
sterol-C5-desaturase (ERG3 delta-5-desaturase 
homolog, S. cerevisiae)-like  
 
a
 SCD NM_005063 stearoyl-CoA desaturase (delta-9-desaturase)  
 
b
 SCD5 NM_001037582 stearoyl-CoA desaturase 5  
 
a
 SGPP1 NM_030791 sphingosine-1-phosphate phosphatase 1  
 
c
 SIRT3 NM_001017524 sirtuin 3  
 
c
 SIRT5 NM_001193267 sirtuin 5  
 
c
 SLC16A12 NM_213606 
solute carrier family 16, member 12 
(monocarboxylic acid transporter 12)  
 
c
 SLC16A14 NM_152527 
solute carrier family 16, member 14 
(monocarboxylic acid transporter 14)  
 
c
 SLC2A1 NM_006516 
solute carrier family 2 (facilitated glucose 
transporter), member 1  
 
c
 SLC2A3 NM_006931 
solute carrier family 2 (facilitated glucose 
transporter), member 3  
 
a
 SORD NM_003104 sorbitol dehydrogenase  
 
a
 SPHK1 NM_001142601 sphingosine kinase 1  
 
c
 SRD5A3 NM_024592 steroid 5 alpha-reductase 3  
 
a





 TP53BP2 NM_001031685 tumour protein p53 binding protein, 2  
 
a,b,c




 TP53INP2 NM_021202 tumour protein p53 inducible nuclear protein 2  
 
c
 UGGT1 NM_020120 UDP-glucose glycoprotein glucosyltransferase 1  
      
 
Several cytokines such as IL-8, IL-13 and IL-16 and cytokine receptor molecules of IL-2, IL-6, 
IL-17A, IL-17D and IL-21 were found to be targets of miR-124a-3p, miR-222 and miR-302a/c. 
Another significant target of interest involved in inflammation is the downstream signalling 
molecule, interleukin-1 receptor associated kinase-1 (IRAK1).  
 
Epigenetic modification of DNA requires the expression and activity of several DNA-methyl-
regulators. It is therefore interesting that a list of targets of miR-124a, miR-222 and miR-
302a/c include the methyl-CpG binding protein (MECP2), methyl-CpG binding domain 
proteins 1 and 2 (MDB1 and MDB2) and DNA (cytosine-5-) methyltransferase 3 beta.  
 
The liver is actively involved in metabolic processing of nutrients, drugs and waste products. 
Most of these processes are energy dependant and require the optimal functioning of the 
mitochondria, the energy hub of all cells. Statin induced overexpression of miRs that target 
crucial molecules for ATP generation: cytochrome c (CYCS) (miR-124a, miR-302a/c), 
cytochrome c assembly factor 5 (COA5) (miR-302a/c), coenzyme Q10 (COQ10B) (miR-
302a/c), ATP synthase mitochondrial F1 complex (ATPAF1) (miR-124a) is therefore an 




 Spermine oxidase, involved in polyamine synthesis, was also identified as a target of miR-
124a. Polyamines are known to play a role in immunomodulation.  
 
The liver and kidney are the two primary sources of creatine which is transported to peripheral 
tissue. The miR-124a specifically targets the mRNA of GAMT, a very important enzyme 
involved in creatine synthesis which catalyses the conversion of guanidinoacetoacetate (GAA) 
to form creatine.  
 
5.3.3 Quantitative analysis of GAMT, AGAT and SMO mRNA expression and western 
blot analysis for GAMT and p53 protein expression  
 
Two targets of miR-124a were chosen to assess the extent by which mRNA levels are 
affected. These include GAMT and SMO. A mechanism of statin induced creatine depletion 
was speculated and the mRNA levels of the enzyme, AGAT (involved upstream of GAMT in 
the creatine synthesis pathway), was assessed. The mRNA level of SMO was selected for 





Figure 5.11 Relative fold changes in mRNA expression of GAMT, AGAT and SMO in 
HepG2 cells treated with atorvastatin, miRNA-124a-3p mimic and miRNA-124a-3p 
inhibitor. 
 
Quantitative PCR was used to determine the effect of atorvastatin treatment on mRNA levels 
GAMT, AGAT and SMO in HepG2 cells. A 1.8-fold decrease in GAMT and 1.15-fold decrease 
in SMO mRNA levels was observed in atorvastatin treated HepG2 cells. An increase in mRNA 
level of AGAT was noted in HepG2 cells treated with atorvastatin by 1.53-fold (Figure 5.11).   
 
In the HepG2 cells transfected with mimics of miR-124a-3p, a similar fold change in mRNA 
levels of GAMT, AGAT, SMO was observed. The reduction in mRNA levels, however, was not 
the same as that noted in the statin treatment with fold changes of 1.41-fold decrease in 
GAMT, 1.2-fold decrease in SMO and a 1.61-fold increase of AGAT. In the presence of the 
miRNA-124a-3p inhibitor, a much higher level of mRNA was detected compared to the control 




The binding of miRNAs to target mRNA sequence does not always translate to a reduction in 
protein expression. Therefore, the protein levels of GAMT in atorvastatin treated cells and 
cells transfected with miR-124a-3p mimics and inhibitors were assessed by western blotting. 
The level of phosphorylated p53, a transcription factor of GAMT, was assessed in atorvastatin 
treated cells and in cells transfected with miR-124a-3p mimics and inhibitors. 
 
The level of GAMT was relatively lower than the untreated control (1.11-fold). HepG2 cells 
transfected with 50nM of miR-124a-3p mimic showed a 1.36-fold decrease in GAMT 
expression. No change in the protein expression of GAMT was noted in the miR-124a-3p 
inhibitor treatment (Figure 5.12). 
 
 
Figure 5.12 Relative fold changes in protein expression of GAMT and phosphorylation 
of p53 (where n=2 and normalised against actin) following treatment with atorvastatin, 




The highest level of p53 phosphorylation was observed in atorvastatin treated HepG2 cells 
(3.2-fold increase). In the presence of the miR-124a-3p mimics the level of p53 
phosphorylation was also higher than the control by 2.1-fold. A similar level of p53 





Statins are unequivocally the most widely prescribed drug for the primary and secondary 
prevention of CVD worldwide (Eidelman et al., 2002).  Atorvastatin is a more commonly 
prescribed drug from the statin family due to its lower therapeutic dose compared to 
simvastatin, lovastatin and cerivastatin (Strandberg et al., 2004). The well-tolerated and high 
benefit-risk ratio of atorvastatin has been demonstrated in clinical trials (Strandberg et al., 
2004).  
 
The liver, being the central hub of metabolism, plays a crucial role in glucose homeostasis, 
cholesterol and lipoprotein synthesis, and xenobiotic metabolism.  
 
Statins have not only received the spotlight for their positive effects, but have also been 
implicated for their adverse effects in patients (Chalasani, 2005). It was reported that liver 
function enzymes rose asymptomatically after therapy. The guidelines for patients on 
atorvastatin therapy recommended a liver function test be performed before administration, 




In our study, we observed an increase in LDH activity after treatment of HepG2 cells with 
atorvastatin (Figure 5.7). This increased LDH activity was only observed at the higher 
concentration of 20µM atorvastatin. LDH activity in cell culture media indicates that 
atorvastatin may have induced membrane damage or leakage due to its lipophilic nature. The 
metabolic activity in hepG2 cells treated with atorvastatin as measured by the MTT (Figure 
5.6) and ATP (Figure 5.7) assays, showed compromised metabolic function. The inhibition of 
HMGCR and subsequent accumulation of acetyl-coA in the mt, can be transported back into 
the cytosol following conversion to citrate. This may lead to a decrease in reducing 
equivalents, and hence the lower levels of MTT conversion and intracellular ATP production.  
 
The positive effects of statins (LDL-C reduction, the protection against oxidative stress, vaso-
relaxant properties of increased NO synthesis and anti-inflammatory potential) out-weigh the 
minor, asymptomatic adverse effects. Statins decreased production of superoxide by 
inhibiting geranylgeranylpyrophosphate (GGPP) activation of ras, preventing the stimulation of 
NADPH oxidase (Wagner et al., 2002; Wassmann et al., 2002; Wang et al., 2008). Also, 
cytosolic citrate undergoes a two-step reaction catalysed by ATP-citrate lyase and malate 
dehydrogenase to form pyruvate. The first reaction utilises NADH and the second produces 
NADPH. Both, the inhibition of NADPH oxidase and the previously mentioned reaction, 
provides NADPH which can be used for the regeneration of the intracellular antioxidant, GSH. 
A significant reduction in lipid peroxidation noted in atorvastatin treated cells (Figure 5.8) in 




The inhibition of eNOS by GGPP occurs via GGPP stimulation of G protein Rho (Figure 5.2). 
Reduced oxidative stress and statin inhibition of HMGCR prevents GGPP formation and 
contributes to increased eNOS activity and an elevation in nitric oxide (Endres, 2005). A 
significant increase in nitrites was observed in atorvastatin treated HepG2 cells (Figure 5.8).  
This strongly suggests that atorvastatin increases eNOS activity. This result is in keeping with 
the antioxidant property of statins. 
 
In the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating 
Rosuvastatin, 17,802 apparently healthy men and women with LDL-C levels of less than 130 
mg/dl (3.4 mmol/l) and high-sensitivity CRP levels of 2.0 mg/l or higher were assessed. It was 
concluded that rosuvastatin significantly reduced the incidence of major cardiovascular events 
in healthy persons without hyperlipidaemia. Of the 17,802 subjects involved in the study, 16% 
presented with muscle weakness, stiffness or pain (Rao and Milbrandt, 2010).  
 
The duration of myopathy from statin therapy ranges from a few weeks to two years (Phillips 
et al., 2002). To date, little is known about the mechanism by which statin therapy leads to 
muscle weakness or fatigue. A study on statin-associated myopathy found pathology even in 
the presence of normal creatine kinase (CK) levels (Phillips et al., 2002). Creatine kinase is 
abundant in energy-demanding tissues such as skeletal muscle. The reaction catalysed by 
CK is the reversible conversion of creatine to phosphocreatine which serves as an energy 
reservoir for the instant regeneration of ATP in situ. Creatine, however, is produced primarily 




Our study assessed the effect of atorvastatin on 84 well characterised miRNAs in the HepG2 
cells and showed a significant increase in several miRNAs species (miR-124a, miR-222 and 
miR-302a/c, Figure 5.10). At least two miRNA panels were used per treatment – hence the 
differentially regulated miRNA’s were validated and repeated using the separate miRNA 
expression assays in which six replicates were analysed. Following an extensive analysis of 
predicted targets of up-regulated miRNAs, several molecules involved in atherosclerotic 
plaque development and progression were identified. The elevated miR-124a and miR-302a/c 
targets integral components of the electron transport chain (CYCS, COA5, COQ10B and 
ATPAF1) as well as a key enzyme in creatine synthesis (GAMT, target of miR-124a).  
 
Figure 5.13 shows a plausible mechanism of statin induced energy depletion which may lead 
to myopathy. In order to validate the proposed mechanism, the mRNA levels of GAMT and 
AGAT – enzymes involved in creatine synthesis -  were assessed and found to be decreased 
by 1.8-fold and increased by 1.53-fold, respectively (Figure 5.11). The lower expression of 
GAMT mRNA by atorvastatin was confirmed by western blotting (Figure 5.12). This decrease 
in protein expression will reduce creatine synthesis. A compensatory mechanism is observed 





Figure 5.13 Targets of miR-124a and miR302a/c which are involved in the electron 
transport chain (Complexes I, II, III, IV, CoQ10: coenzyme Q10), creatine (arg: arginine, 
Gly: glycine, AGAT: arginine glycine aminotransferase, GAA: guanidinoacetoacetate, 
GAMT: guanidinoacetate aminotransferase) and polyamine (Orn: ornithine, SMO: 
spermine oxidase) synthesis pathways.  
 
 
A study on left ventricular assist devices (LVADs) used to support a failing heart (found an 
unexpected elevation of AGAT mRNA levels in these patients compared to healthy donors. 
These patients were placed on pharmacological therapy of β2-adrenergic agonists to improve 
cardiac function (Cullen et al., 2006). The authors however, did not use statin therapy as an 
exclusion criterion nor was the percentage of patients on statin therapy stated (Cullen et al., 
2006). The compromised synthesis of creatine from the liver in the presence of statin therapy 
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may result in the increased expression of AGAT in the myocardium as a compensatory 
mechanism for the energy demands of the heart.  
 
There is emerging evidence that p53 is involved in the regulation of energy metabolism and 
autophagy (Feng et al., 2005; Crighton et al., 2006; Bensaad and Vousden, 2007; Jones and 
Thompson, 2009). Metabolic activity of p53 is related to adenosine monophosphate kinase 
(AMPK) (Jones and Thompson, 2009), TP53-induced glycolysis and apoptosis regulator 
(TIGAR) (Bensaad and Vousden, 2007) and phosphoglycerate mutase (PGM) (Kondoh et al., 
2005). Mutant cells lacking p53 showed enhanced glycolysis with decreased utilization of 
oxygen by mt respiration, commonly referred to as the Warburg effect (Bensaad and 
Vousden, 2007). A study on a link between p53, GAMT and FA oxidation provided new insight 
to the cells’ response to nutrient availability (Ide et al., 2009). This study identified p53 
activation (phosphorylation) under conditions of nutrient stress, which led to creatine 
biosynthesis and FA oxidation as an alternate source to regulate energy metabolism (Ide et 
al., 2009).  
 
Our study atorvastatin elevated levels of miR-124a in the liver cells. The targets included the 
electron transport chain, and GAMT - both essential for creatine synthesis. The level of ATP 
in atorvastatin treated cells was lower than control cells, with no statistical significance. This 
change in AMP/ATP ratio will result in the phosphorylation of p53.    The western blot results 
confirmed an increased phosphorylation of p53 in the presence of atorvastatin (Figure 5.12). 
The role of p53 in energy regulation leads to increased expression of GAMT and FA oxidation 
(Ide et al., 2009). In the presence of statin induced miR-124a-3p inhibition of GAMT, the 
alternate source of FAs would be utilized to compensate for energy requirements. This may 
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explain the decrease in free FA and triglycerides in circulation of patients on statin therapy. 
Furthermore, the upregulation of creatine kinase levels in patients on statins could possibly be 
a compensatory mechanism to preserve creatine stores.  
  
A by-product of the AGAT catalysed reaction utilising L-arginine (Arg) and glycine (Gly) as 
substrates to form guanoacetoacetate, is ornithine (Orn) (Figure 5.6). Ornithine may then 
either enter the urea cycle or the polyamine synthesis pathway. Spermine oxidase, also a 
target of miR-124a, catalyses the conversion of spermine to spermidine, and when inhibited 
(1.15-fold in this study), results in an increase in spermine levels. The range of biological roles 
of spermine includes acting as a second messenger in cell signalling, regulation of DNA 
synthesis, cellular proliferation and inhibition of the immune response (Seiler and Atanassov, 
1994). A study assessing the effects of spermine on stimulated human peripheral blood 
nuclear cells found an inhibition of pro-inflammatory cytokine synthesis: TNFα, IL-1 and IL-6 
(Zhang et al., 1999).  
 
The lipid-lowering properties of statins are well documented (Ebrahim et al., 1999; Heart 
Protection Study Collaborative Group, 2002; Law et al., 2003). In the CARE clinical trials 
(Ridker et al., 1998), statins were recognised for their anti-inflammatory effects. Since 
cytokines have been implicated as key mediators of atherosclerotic plaque development and 
progression, they have also become therapeutic targets of interest (von der Thusen et al., 
2003). The inhibition of the synthesis of interleukins-8, -13 and -16, interleukin receptor 2 (IL-
2R), 6 (IL-6R), 17A (IL-17AR), 17D (IL-17DR) and 21 (IL-21R) and IRAK1 are targets of 
statin-induced up-regulation of miR-124a, miR-222 and miR-302a/c. This may explain the 
anti-inflammatory effects of statin therapy. In hepatic cells IL-6R and IRAK1 are integral for 
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the binding of IL-6 and the downstream signalling of IL-1 ultimately resulting in the synthesis 
and release of CRP. A decrease in the levels of IRAK1 leads to reduced CRP synthesis in the 
presence of statins. In the clinical setting, this is a valuable finding as pro-inflammatory 
markers in circulation are reduced in patients on statin therapy.  
 
The up-regulated miRNAs targeting the inflammasome appear to play role in regulating 
cytokine levels and their actions. This implies that and in conjunction with the presence of 
SNPs (IL-6 and CDRP) investigated in chapter 4, a more complex mechanism of control is 
present. A recent study found attenuated IL-6 production, decreased mRNA and protein levels 
of IL-6R and subsequent inhibition of STAT3 phosphorylation by added miR-124 in liver cell 
lines (Hatziapostolou et al., 2011). The mechanism of statin-reduced pro-inflammatory 
cytokine may be a result of up-regulation of miRNA-124. This may be necessary for CAD 
patients as inflammation is critical in the progression of atherosclerosis. Hence, the anti-
inflammatory effects of statins may not only be a direct result of cytokine and cytokine 





Atorvastatin limits metabolic activity and energy availability in hepG2 cells. Minimal 
cytotoxicity (LDH leakage) was noted with atorvastatin treatment. The antioxidant potential of 
atorvastatin was confirmed by a decrease in lipid peroxidation. The increase in nitric oxide 
production, also confirms the ability of statins to increase eNOS activity. Statin treated HepG2 
cells exhibit a different miRNA profile compared to untreated controls. An assessment of 
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targets of up-regulated miR-124a, miR-222 and miR-302a/c show they play a crucial role in 
the regulation of inflammation (IL-6 and IRAK1, specifically) and metabolism (lipoprotein 
receptors and transporters, lipid and carbohydrate metabolism associated enzymes, 
specifically). The inhibition of GAMT by miR-124a may explain the creatine depletion and 
elevated creatine kinase levels observed in the clinical setting. The anti-inflammatory potential 
may also be attributed to the miR-124a inhibition of spermine oxidase. Taken together, 





















Preparation of samples of known concentration for the IL-6 ELISA 
 
Standard Concentration Volume IL-6  Volume Distilled water 
150 ρmol 50.0 μl 50.00 μl 
75 ρmol 25.0 μl 75.00 μl 
37.5 ρmol 12.5 μl 87.50 μl 
18.8 ρmol 6.25 μl 93.75 μl 
9.4 ρmol 3.13 μl 96.87 μl 
4.7 ρmol 1.56 μl 98.44 μl 
0.00 ρmol 0.00 μl 100.0 μl 
 
 
Standard curve derived from the IL-6 standards. 
 
Standard IL-6 concentrations were prepared and used to create the standard curve above. 
The curve was extrapolated and the equation (y=0.002x + 0.049) used to determine the 















































Component Concentration (mg/l) 





NaCl 8 000.0 
NaHCO3 350.0 
Na2HPO4.7H2O 90.0 
Other components  
Glucose 1 000.0 
Phenol red 20.0 
Amino acids  
L-Arginine-HCl 126.4 













Choline chloride 1.0 










THE 2-ΔΔCt METHOD FOR ANALYSIS OF QUANTITATIVE PCR 
 
The 2-ΔΔCt method refers to the method of analysis used to obtain a relative fold change of a 
treated sample compared to an appropriate control group as described by Livak and 
Schmittgen (2001). The table below extracted directly from the original article highlights an 













           
 Protein Quantification and Standardisation  
     Bovine serum albumin (mg/ml)    
     0 0.2 0.4 0.6 0.8 1    
   OD1 0.001 0.212 0.432 0.674 0.821 1.021    
   OD2 0.003 0.221 0.453 0.684 0.842 1.033    
   OD3 0.003 0.219 0.429 0.668 0.844 1.023    
   Average 0.00 0.22 0.44 0.68 0.84 1.03    
                    
 
                    
       Control Statin mimic inhibitor      
   OD1   0.986 0.976 0.968 0.991      
   OD2   0.978 0.976 0.97 0.982      
   OD3   0.988 0.987 0.978 0.984      
   Average   0.984 0.979667 0.972 0.985667      
   
Initial concentration 
 
(mg/ml) 0.940 0.936 0.928 0.941 
   
   
Final concentration 
 
(mg/ml) 0.9 0.9 0.9 0.9 
   
   
Final volume 
 
(ul) 150 150 150 150 
   
   
Initial volume 
 
(ul) 144 144 145 143 






miR Pathway Finder Array - Control vs. Atorvastatin 
Observation Residual Rank Rank prop r based z score Residual 
miR-19a -3.63 1 0.01 -2.51 -3.63 
miR-101 -2.92 2 0.02 -2.09 -2.92 
let-7g -2.81 3 0.03 -1.87 -2.81 
let-7f -2.8 4 0.04 -1.72 -2.80 
miR-140-5p -2.78 5 0.05 -1.60 -2.78 
miR-26b -2.78 6 0.07 -1.50 -2.78 
miR-126 -2.75 7 0.08 -1.41 -2.75 
miR-425 -2.71 8 0.09 -1.33 -2.71 
let-7e -2.44 9 0.10 -1.26 -2.44 
let-7a -2.41 10 0.12 -1.20 -2.41 
miR-29a -2.35 11 0.13 -1.14 -2.35 
miR-24 -2.26 12 0.14 -1.08 -2.26 
miR-29c -2.22 13 0.15 -1.03 -2.22 
miR-194 -2.18 14 0.16 -0.98 -2.18 
miR-27a -2.1 15 0.18 -0.93 -2.10 
miR-20a -2.01 16 0.19 -0.88 -2.01 
miR-30e -2. 17 0.20 -0.84 -2.00 
miR-30d -1.93 18 0.21 -0.79 -1.93 
miR-26a -1.92 19 0.23 -0.75 -1.92 
miR-27b -1.88 20 0.24 -0.71 -1.88 
miR-100 -1.87 21 0.25 -0.67 -1.87 
miR-15b -1.87 22 0.26 -0.64 -1.87 
miR-19b -1.84 23 0.27 -0.60 -1.84 
miR-99a -1.81 24 0.29 -0.56 -1.81 
miR-424 -1.75 25 0.30 -0.53 -1.75 
miR-9 -1.72 26 0.31 -0.49 -1.72 
miR-30a -1.72 27 0.32 -0.46 -1.72 
miR-17 -1.49 28 0.34 -0.43 -1.49 
miR-30c -1.42 29 0.35 -0.39 -1.42 
miR-93 -1.3 30 0.36 -0.36 -1.30 
miR-195 -1.22 31 0.37 -0.33 -1.22 
miR-16 -1.18 32 0.38 -0.29 -1.18 
miR-125a-5p -1.15 33 0.40 -0.26 -1.15 
miR-125b -1.09 34 0.41 -0.23 -1.09 
miR-30b -0.99 35 0.42 -0.20 -0.99 
miR-25 -0.8 36 0.43 -0.17 -0.80 
miR-151-5p -0.78 37 0.45 -0.14 -0.78 
miR-7 -0.72 38 0.46 -0.11 -0.72 
miR-23a -0.67 39 0.47 -0.08 -0.67 
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miR-21 -0.59 40 0.48 -0.05 -0.59 
miR-374a -0.56 41 0.49 -0.02 -0.56 
miR-28-5p -0.51 42 0.51 0.02 -0.51 
miR-374b -0.46 43 0.52 0.05 -0.46 
miR-23b -0.45 44 0.53 0.08 -0.45 
miR-191 -0.17 45 0.54 0.11 -0.17 
miR-103 0.41 46 0.55 0.14 0.41 
miR-28-3p 0.47 47 0.57 0.17 0.47 
let-7i 0.78 48 0.58 0.20 0.78 
miR-320a 0.86 49 0.59 0.23 0.86 
miR-376c 0.88 50 0.60 0.26 0.88 
let-7c 0.97 51 0.62 0.29 0.97 
miR-22 1. 52 0.63 0.33 1.00 
miR-92a 1.12 53 0.64 0.36 1.12 
miR-143 1.29 54 0.65 0.39 1.29 
miR-15a 1.63 55 0.66 0.43 1.63 
miR-32 1.7 56 0.68 0.46 1.70 
miR-106b 1.75 57 0.69 0.49 1.75 
miR-181b 1.77 58 0.70 0.53 1.77 
miR-140-3p 1.79 59 0.71 0.56 1.79 
miR-29b 1.84 60 0.73 0.60 1.84 
miR-186 2.03 61 0.74 0.64 2.03 
miR-181a 2.07 62 0.75 0.67 2.07 
miR-196b 2.07 63 0.76 0.71 2.07 
miR-142-5p 2.16 64 0.77 0.75 2.16 
miR-128 2.18 65 0.79 0.79 2.18 
miR-146a 2.19 66 0.80 0.84 2.19 
miR-223 2.24 67 0.81 0.88 2.24 
miR-122 2.25 68 0.82 0.93 2.25 
miR-144 2.25 69 0.84 0.98 2.25 
miR-185 2.36 70 0.85 1.03 2.36 
let-7b 2.58 71 0.86 1.08 2.58 
miR-150 2.62 72 0.87 1.14 2.62 
miR-302b 2.62 73 0.88 1.20 2.62 
miR-210 2.69 74 0.90 1.26 2.69 
miR-141 2.74 75 0.91 1.33 2.74 
let-7d 2.77 76 0.92 1.41 2.77 
miR-130a 3.01 77 0.93 1.50 3.01 
miR-200c 3.02 78 0.95 1.60 3.02 
miR-302a 3.05 79 0.96 1.72 3.05 
miR-302c 3.61 80 0.97 1.87 3.61 
miR-124 3.9 81 0.98 2.09 3.90 
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